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Abstract 
Staphylococcus aureus is a component of normal flora colonizing skin and nares, but it is also 
one of the most common causes of serious infections, especially sepsis. The dysfunctional 
immune response during sepsis often leads to tissue damage and organ failure, including acute 
lung injury. Among the virulence factors that likely drive the high morbidity and mortality 
associated with S. aureus sepsis and tissue injury are enterotoxins, including S. aureus 
enterotoxin A (SEA). SEA directly crosslinks MHC II molecules and specific Vβ chains of T cell 
receptors resulting in oligoclonal activation of T cells and massive immune response. Previous 
studies showed that SEA inhalation in mice caused a rapid activation of SEA-specific T cells 
and cytokine release into circulation. This systemic inflammatory response was followed by 
SEA-specific T cell expansion in lymphoid tissues and lung, which was accompanied by 
development of pulmonary pathology and increased vascular permeability. The aims of this 
study were to (1) define the crosstalk between adaptive immunity and innate immune cells 
during the systemic inflammatory response, (2) further characterize SEA-induced pulmonary 
inflammation and understand the mechanism leading to increased permeability in lung, and (3) 
determine the role of alveolar macrophages in the systemic inflammatory response due to SEA 
inhalation. The results demonstrated that after inhalation, SEA disseminated systemically via 
blood and triggered rapid transcriptional changes in T cells followed by a systemic recruitment 
of neutrophils and monocytes into circulation and lymphoid tissues. TNF and CD28 signaling 
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played unique but also overlapping roles in the migration of innate immune cells. Furthermore, 
this study shows that the injury to the pulmonary endothelial cells was dependent both on early 
immune responses due to T cell activation as well as on later inflammatory processes through 
CD54 engagement. Finally, alveolar macrophages were shown to play a critical role in binding 
SEA within the lung mucosa and their ablation was associated with increased T cell activation 
and cytokine release.  Altogether, these findings demonstrated the elaborate pathways involved 
in SEA-evoked inflammation. Understanding the mechanisms of S. aureus enterotoxin-induced 
systemic and pulmonary response may unravel novel therapeutic options for S. aureus 
infections. 	
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Chapter 1: Introduction 
 
General comments 
Acute inflammation is a rapid and vital reaction to injury, trauma or infection. The goal of 
acute inflammatory response is to activate local cells (e.g. tissue macrophages or endothelium), 
recruit leukocytes and induce a milieu of pro- and anti-inflammatory mediators, which eventually 
leads to resolution of inflammation, healing and tissue regeneration.  In certain instances, 
however, it may also result in further propagation of the inflammatory response and organ 
dysfunction (1). Typical examples of excessive inflammatory response causing tissue damage 
include systemic inflammatory response syndrome (SIRS) and the related sepsis as well as 
acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Understanding how acute 
inflammation is contained, how it subsides and how it becomes uncontrolled and exaggerated is 
crucial for the development of better therapeutic strategies.  
A key cellular component of acute inflammatory response is the innate immune system, 
particularly, neutrophils, monocytes, and macrophages. These cells can be quickly activated 
and recruited to the site of injury. Furthermore, they can mount relatively nonspecific defense 
mechanisms against various inflammatory, nocuous, or alarm signals. These mechanisms 
include phagocytosis and release of reactive oxygen species, cytokines, chemokines, lytic 
enzymes and other mediators (2-4). Because of their ability to elicit a rapid and robust 
nonspecific immune response, innate immune cells are thought to be the mediators of tissue 
damage in cases of overly activated immune response, i.e. in SIRS/sepsis or ALI/ARDS. Thus, 
innate immune responses and particularly neutrophils have been targeted in many studies in 
order to develop novel treatments for these life-threatening conditions (5, 6). Unfortunately, 
there is currently no approved pharmacotherapy for the treatment of SIRS/sepsis and ALI/ARDS 
(7, 8). A part of the issue is undoubtedly the fact that these conditions have an overly complex 
etiology and pathophysiology, and they involve a plethora of villainous mediators. Thus, 
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targeting a single agent may not be sufficient to achieve therapeutic success in all patients. 
However, it is also likely that an important part of the immune response has been neglected 
over the years in the study of injurious, excessive inflammation: the adaptive immunity and 
particularly T cells.  
Adaptive immune response is usually considered delayed compared to the innate 
immunity. Nevertheless, it can also induce a rapid and over-exuberant inflammation when 
stimulated with specific agents. This is particularly relevant in the case of superantigens. 
Superantigens, such as S. aureus enterotoxins, are known for their ability to trigger oligoclonal 
activation of T cells and a cytokine storm. This rapid T-cell mediated inflammatory response can 
cause serious organ injury and even death (9, 10). This work explores the mechanisms of S. 
aureus enterotoxin-induced inflammation and uncovers potential therapeutic targets. The first 
chapter introduces the topics of S. aureus enterotoxins, SIRS and ALI. The second chapter 
contains materials and methods used in the experimental studies. Chapter 3 investigates 
systemic inflammatory response in the context of S. aureus enterotoxin. Chapter 4 focuses on 
the mechanisms of pulmonary inflammation due to S. aureus enterotoxin. Chapter 5 explores 
the role of alveolar macrophages in S. aureus enterotoxin-induced inflammation. Finally, chapter 
6 offers concluding remarks and future directions.  
 
Staphylococcus aureus and superantigens 
Staphylococcus aureus is a Gram-positive, facultative aerobe that colonizes anterior 
nares, pharynx, or skin in asymptomatic individuals. In fact, 20% (range 12-30%) of the general 
population has a persistent nasal carriage of S. aureus and 30% (range 16-70%) are 
intermittent carriers (11). However, in addition to being a commensal organism, S. aureus is 
also recognized as one of most significant causes of life-threatening infectious diseases in the 
United States (9, 12). In particular, the methicillin-resistant form of S. aureus (MRSA) poses a 
major threat in hospital settings (12, 13) and although the incidence of MRSA in the United 
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States has been declining likely due to better prevention strategies, it is currently estimated to 
cause over 80,000 cases of invasive infections annually (14). Because of its versatile virulence 
factors, S. aureus can evade the immune defenses of the host and cause a variety of infections: 
including benign soft tissue abscesses as well as life-threatening infections such as bacteremia 
and sepsis, pneumonia, endocarditis or osteomyelitis (12, 15). Among the wide array of 
secreted or surface-bound virulence factors is a group of toxins known as superantigens.  
Superantigens, such as S. aureus enterotoxins, are nonglycosylated low-molecular-
weight exotoxins (9). There are about 40 different bacterial superantigens that are typically 
produced by S. aureus or Streptococci species (10). Staphylococcal superatigens are usually 
encoded by accessory genetic elements, such as prophages, plasmids, transposons, or 
pathogenicity islands and thus, they are not uniformly present in all clinical isolates (10). 
Nevertheless, it has been reported that the majority of strains carry at least one superantigen 
gene (9, 16-18). The regulation of superantigen synthesis by the bacteria is currently not well 
understood but at least in the case of S. aureus enterotoxins it appears to be induced during or 
at the end of the exponential growth phase (19, 20). 
Superantigens have a unique ability to bypass antigen processing and directly bind to 
the major histocompatibility complex class II (MHC II) of antigen presenting cells (APCs). In fact, 
even metabolically inactivated APCs are still capable of presenting a superantigen (21, 22). The 
binding of superantigens to MHC II is extremely stable and can generally occur through the α 
chain and in some cases also the β chain of MHC II (10). After directly binding to MHC II, 
superantigens can then crosslink it with specific Vβ chains of T cell receptors (TCRs). The 
engagement of Vβ chains is determined by the shallow cavity at the top of the protein (10, 23). 
Superantigens are also much more promiscuous compared to other antigens. Each 
superantigen can bind to several different Vβ regions; for example, in mice, S. aureus 
enterotoxin A (SEA) can bind to Vβ1, 3, 10, 11 and 17. Furthermore, whereas conventional 
antigens are restricted by MHC I and MHC II binding, superantigens can activate both CD4+ and 
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CD8+ T cells with a specific TCR Vβ chain (23). Thus, compared to conventional antigens which 
usually activate 1/104-106 T cells, superantigens can stimulate up to 1/4 T cells (22). This rapid 
activation of a large number of T cells causes a cytokine storm and the elevated levels of IL-2, 
TNF and IFNγ in the bloodstream are generally believed to be the main cause of toxicity (10). 
 Furthermore, as the term “enterotoxin” indicates, some S. aureus enterotoxins possess 
a strong emetic activity and in fact, ingestion of superantigens is a major cause of food 
poisoning (24). The mechanism of emesis induction is not completely understood. However, the 
presence of a cystine loop seems be required for emetic activity while it appears to be 
independent of MHC II and TCR binding (9, 24), In addition to their ability to induce systemic or 
enteric toxicity, most superantigens are remarkably stable: they are resistant to heat, boiling, 
acids, proteolysis and dessication. Thus, their biological toxicity and environmental stability 
makes them extremely dangerous agents and some are currently categorized as potential 
weapons of bioterrorism (9).  
Although all superantigens share their ability to stimulate a large number of T cells, they 
exhibit different binding properties to MHC II as well as different emetic activity depending on 
the presence of the cystine loop. These structural features can be used to separate 
superantigens into 5 groups. Table 1.1 represents categorization of staphylococcal 
superantigens (adapted from Spaulding et al. (9)). The ability to engage not only the α chain but 
also the β chain of MHC II appears to play a critical role in the overall potency. In particular, the 
second binding site to the β chain of MHC II also known as Zn2+-dependent MHC II binding site 
increases the persistence of a superantigen on cell surface and may allow for crosslinking of 
adjacent APCs (25, 26).  Thus, superantigens that bind both the α and the β chains of MHC II 
have about 10- to 100-fold greater toxicity compared to superantigens binding only to the α 
chain (9). Finally, recent studies identified two other important engagement sites for 
superantigens, the costimulatory receptor CD28 on T cells and its ligand CD86 on APCs (27, 
28).  Direct binding of a superantigen to these sites enhances the CD28/CD86 costimulation 
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axis and it appears to play a crucial role in the extent of T cell activation, cytokine storm and 
overall lethality due to a superantigen exposure (27-29).     
 
Immune response to superantigens 
The ability of superantigens like S. aureus enterotoxins to directly bind to MHC II 
molecules and bridge them with specific Vβ chains of TCRs triggers a potent immune response. 
First, the high affinity of superantigens for MHC II induces a rapid activation of T cells. In fact, as 
early as 1 h after SEA inhalation, the early T cell activation antigen CD69 was upregulated on 
about 80% of SEA-specific T cells in mediastinal lymph nodes (LNs) and by 5 h, about 80% of 
SEA-specific T cells were positive for both CD69 and IL-2 receptor, CD25 (30). Upon activation, 
T cells and APCs respond by releasing a number of different cytokines and chemokines. In 
particular, the production of IL-2, TNF, and IFNγ by T cells is a pronounced feature of a 
superantigen exposure (31-33). Together with other cytokines and chemokines, such as IL-6, 
IL-12, or CCL2 (34, 35), this so-called cytokine storm is thought to mediate the serious 
symptoms of toxic shock (10, 36).  
Superantigens and particularly S. aureus enterotoxins were initially described as potent 
T cell mitogens (37, 38).  Following activation, superantigen-specific T cell populations undergo 
5-6 rounds of division, resulting in a significant accumulation of T cells (23, 34, 39, 40). For 
instance, in a model of SEA inhalation in mice, Vβ3+ SEA-specific T cells underwent a massive 
expansion in all lymphoid tissues as well as the lung by 2 days after exposure. Apart from the 
actual numbers, the percentage of Vβ3+ T cells in the spleen increased from about 3% to 30% of 
the total T cell population (39). In addition, superantigen-stimulated T cells exhibit effector and 
cytotoxic phenotype. In particular, 2 or 3 days following S. aureus enterotoxin exposure, CD8+ T 
cells were shown to express high levels of IFNγ, granzyme B, and perforin (30, 39, 41) and their 
accumulation in lung was associated with increased cell number and protein concentration in 
the bronchoalveolar lavage (BAL) fluid, indicating tissue injury (39).  
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Following expansion, superantigen-specific T cells undergo clonal deletion or 
programmed death (42-45). The activation-induced cell death (AICD) due to S. aureus 
enterotoxin was found to only occur in proliferating T cells and the apoptotic cells upregulated 
CD95 (Fas) as well as CD178 (FasL) (46, 47). Interestingly, AICD could be prevented when 
mice were simultaneously exposed to bacterial lipopolysaccharide (LPS). The survival of T cells 
was dependent on TNF and to a lesser extent IFNγ and the rescued T cells were unresponsive 
to Fas engagement (48).  
Not all specific T cells become deleted and these cells display an anergic phenotype 
(49-51), defined as inability to proliferate or produce cytokines upon restimulation (52). There 
are two proposed mechanisms of superantigen-induced T cell anergy: intrinsic and extrinsic. An 
intrinsic deficit is characterized as inert change in cell signaling or transcriptional activity. 
Several studies reported molecular changes in TCR signaling of anergic cells, particularly 
defective protein phosphorylation and altered function of transcriptional factor AP-1 (53, 54). 
The presence of an intrinsic anergic state was also shown using in vivo transfer experiments 
where anergic T cells transferred to a naïve recipient failed to proliferate upon S. aureus 
enterotoxin restimulation while naïve T cells transferred into an anergic recipient proliferated 
(55). In contrast, an extrinsic deficit would be attributed to an outside suppressor, such as 
cytokine or cell-to-cell contact. In particular, mechanistically, it was shown that anergy of CD4+ T 
cells was dependent on the presence of myeloid cells, NO synthase activity, reactive oxygen 
species, and IFNγ (52, 56). An important source of IFNγ are CD8+ T cells (39); indeed, CD4+ T 
cell anergy was enforced by CD8+ T cells (57). Furthermore, the unresponsiveness of 
superantigens could be attributed to immunosuppression due to augmentation of Treg 
population (58-60). Recently, it was also proposed that superantigen interaction with APCs not 
only induces pro-inflammatory responses but also plays a role in inducing unresponsiveness 
through increased expression of IL-10, programmed death ligand-1 (PD-L1), also 
immunosuppressive molecule indoleamine 2,3-dioxygenase - IDO (61). 
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Finally, it is important to note that there are some differences between human and 
mouse responses to superantigens. Human T cells are exquisitely sensitive to superantigens. In 
some cases, human T cells cultured in vitro can respond to 1 fg/mL of superantigen (10). 
Furthermore, it has been estimated that an amount of 0.0013 µg/kg of body weight could be life 
threatening to a human. In contrast, mice are quite resistant to superantigens and unless they 
are genetically modified or pre-treated with sensitizing agents, such as D-galactosamine, they 
do not generally develop symptoms of toxic shock or succumb to superantigens (62). 
Nevertheless, similarly to humans, murine immune system responds to superantigens by 
oligoclonal activation and expansion of T cells, cytokine release, as well as the subsequent T 
cell anergy (31-33, 40, 44, 63, 64). Thus, studying these responses can lead to a better 
understanding of the pathology and eventually to a development of novel treatments.  
 
Role of superantigens in systemic and pulmonary diseases 
Superantigens were initially associated with a condition known as toxic shock syndrome 
during its outbreak in children in the late 1970s (65). Since then, the involvement of 
superantigens in the pathology of various human diseases has been a focus of many studies. 
Some of the recognized illnesses linked to superantigens include food poisoning, atopic 
dermatitis, and allergic rhinitis (10). Recent evidence has also demonstrated a causal 
relationship between staphylococcal superantigens and S. aureus pneumonia and sepsis (9). 
These conditions are discussed below in greater detail. 
 
Toxic shock syndrome 
Toxic shock syndrome is a systemic response to superantigen exposure, particularly 
toxic shock syndrome toxin-1 (TSST-1) and S. aureus enterotoxins. By 1980, several studies 
reported development of toxic shock in young menstruating women, which was related to the 
use of high absorbency tampons and the presence of TSST-1 (9, 66-68). In contrast, non-
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menstrual toxic shock syndrome may result from any primary S. aureus infection and can be 
caused by TSST-1 as well as S. aureus enterotoxin A, B, or C (36, 69). In addition, while there 
was no mortality in menstrual toxic shock syndrome, non-menstrual toxic shock syndrome 
cases had a mortality of 22% (70). The classical symptoms of toxic shock syndrome resemble 
influenza-like illness and include high fever, vomiting, diarrhea, headache, sore throat, myalgia, 
and erythematous, desquamating rash (10, 36). Following the outbreak of menstrual toxic shock 
syndrome in the 1980s, the incidence of the disease has been considered relatively low; 
however, it is likely that a lack of a diagnostic test and the stringent definition of characteristic 
symptoms lead to an underestimation of the actual rates (69).  
 
Systemic inflammatory response syndrome and sepsis 
 SIRS and the related sepsis are devastating medical conditions with increasing 
incidence worldwide and no available pharmacotherapy (7). SIRS is a broad term used to define 
a group of systemic symptoms that occur as a physiologic response to a variety of acute insults, 
such as infection, trauma, hemorrhage or immune-mediated organ injury (71) . A recent study 
estimated that SIRS occurs in over 16 million adult patients in the emergency department within 
the United States annually (71). The symptoms of SIRS include tachycardia (heart rate >90 
beats/min), tachypnea (respiratory rate >20 breaths/min or partial pressure of carbon dioxide 
PaCO2 <32 mmHg), fever or hypothermia (temperature >38.5°C or <35°C) and changes in white 
blood cell count (WBC); either increase in WBC of more than 12,000 cells/mm3 or decrease in 
WBC of less than 4000 cells/mm3 (7, 72). Sepsis is often defined as SIRS in the presence of a 
known or suspected infection and is thought to affect more than 1,000,000 people in the United 
States every year (7, 73). Although recent advances in critical care reduced the overall rate of 
in-hospital deaths, the mortality due to sepsis remains unacceptably high with estimates 
between 20-30%. Furthermore, the surviving patients remain at increased risk for death even 
after recovery and may suffer from impaired physical and neurocognitive functioning (72). 
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The general mechanism of SIRS/sepsis pathophysiology is shown in Fig. 1.1. Following 
an inflammatory trigger, such as pneumonia, trauma or surgery, the immune system and 
specifically innate cells - neutrophils, monocytes and macrophages - become activated (e.g. 
through pattern recognition receptors) and trigger a robust inflammatory response, involving 
cytokines, chemokines, the complement system as well as platelets. Similarly, the adaptive 
immunity and particularly T cells can get stimulated upon interaction with APCs. Both pro- and 
anti-inflammatory factors can be released simultaneously; therefore, patients may present with 
either hyperinflammatory state (SIRS) or immunosuppressive state (compensatory anti-
inflammatory response syndrome or CARS). These changes may be accompanied by 
coagulation abnormalities, which can manifest as disseminated intravascular coagulation (DIC) 
as well as impaired neuroendocrine regulation that normally controls aspects of 
immunosuppressive mechanisms. Together, these systemic responses can lead to increased 
oxidative stress, tissue hypoperfusion, and loss of barrier function (72, 74, 75). Tissue injury 
may lead to organ dysfunction and if several organs are involved (e.g. lung or kidney), it is 
known as multiple organ dysfunction syndrome (7). Finally, if patients suffer from hypotension 
refractory to fluid resuscitation, they are in septic shock, a serious condition with a high mortality 
rate (72).  
While initially the predominant causative organisms were Gram-negative bacteria, more 
recent data demonstrated an increasing incidence of Gram-positive bacteria and fungi. In 
particular, Gram-positive bacteria were found in 37.6% of cases (76). Even more recently, a 
large epidemiologic study of serious infections in intensive care units found Gram-positive 
bacteria in 47% of patients with S. aureus present in 20% (77). In Gram-negative bacteria, LPS 
plays a dominant role in initiating the inflammatory cascade in sepsis. However, Gram-positive 
bacteria do not have LPS and possess other virulence factors, such as superantigens (78).  In 
fact, superantigen-expressing S. aureus strains or superantigen proteins were found in septic 
patients, and the prevalence of SEA correlated with the severity of the disease (79-81). SEA 
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was also found in 25% of burn injury patients (population susceptible to serious infections and 
sepsis) and its presence increased the likelihood of mortality by 11% (82). Furthermore, a 
recent study demonstrated that neutralization of superantigen S. aureus enterotoxin K present 
in the common MRSA strain USA300 increased survival in an intravenous challenge model in 
mice (83). Similarly, neutralization of S. aureus enterotoxin B in a mouse model of MRSA 
infection prevented lethal sepsis and reduced skin tissue invasion and abscess formation (84). 
Finally, the presence of superantigen S. aureus enterotoxin C was critical in inducing tissue 
injury and driving lethality in a rabbit model of S. aureus sepsis (85).  
 
Pneumonia, acute lung injury and acute respiratory distress syndrome 
 ALI/ARDS affects 200,000 adults in the United States annually and has a mortality of 
about 40% (86). Furthermore, a recent multinational epidemiologic study identified that over 
10% of intensive care unit patients develop this devastating condition, suggesting that 
ALI/ARDS is largely underdiagnosed (87). ALI is characterized by bilateral pulmonary infiltrates 
with arterial hypoxemia due to accumulation of edema fluid and impaired gas exchange (the 
concentration of arterial oxygen divided by the inspired fraction of oxygen PaO2/FiO2 <300). If 
PaO2/FiO2 <200, the patient is diagnosed with ARDS (88). ALI/ARDS can be caused by direct 
(pulmonary) and indirect (extrapulmonary) causes. Direct causes include pneumonia, aspiration, 
pulmonary contusion, or toxic inhalation, whereas indirect causes include sepsis, extrathoracic 
trauma, burn injury, drug overdose, or pancreatitis (89). However, pneumonia and sepsis 
represent the most common triggers. The hallmark of ALI/ARDS pathology is increased 
vascular permeability due to endothelial injury. This is accompanied by injury to the lung 
epithelial cells, pulmonary edema, accumulation of red blood cells and immune cells in the lung 
tissue, particularly neutrophils, macrophages, and monocytes (88). The mechanism of 
ALI/ARDS is not fully understood; however, because of the significant neutrophil infiltration, 
neutrophils are often considered to be a critical part of the pathogenesis (88).  
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Despite a number of clinical trials, there is currently no pharmacotherapy for the 
treatment of ALI/ARDS. These included clinical trials testing treatments focused on inhibition of 
neutrophil and macrophage function, such as neutrophil elastase inhibitor or antioxidant N-
acetylcysteine, and they showed no change in mortality (8). Thus, it is likely that other 
mechanisms are in place that may drive the pathology in ALI/ARDS. In particular, the role of T 
cells in the pathogenesis of ARDS is only now beginning to emerge (90). Previous studies 
demonstrated that there were elevated numbers of lymphocytes in the blood and BAL fluid of 
ALI/ARDS patients (91, 92). Furthermore, ALI/ARDS patients also showed an increase in a T 
cell specific cytokine IL-2 in the BAL fluid and its levels were correlated with increased mortality 
(93, 94). One potential explanation for the presence of T cells in ALI/ARDS is superantigens. In 
fact, the involvement of superantigens in a number of airway diseases, such as allergic rhinitis, 
nasal polyposis and asthma has been a focus of many studies (95). Moreover, recent reports 
demonstrated that preimmunization against superantigens prevented fatal necrotizing 
pneumonia in rabbits infected with a common USA200 MRSA strain (96, 97). Finally, 
aerosolized S. aureus enterotoxin caused serious pulmonary inflammation and death in 3 out of 
6 rhesus monkeys (98). Unfortunately, there is currently a lack of human studies that would link 
superantigens to sepsis- or pneumonia-induced ALI/ARDS. Such studies will be necessary to 
confirm the role of superantigens in ALI/ARDS.  
  
The model of S. aureus enterotoxin inhalation in mice 
S. aureus enterotoxins and other superantigens are known to induce robust systemic 
responses, but how they spread systemically is not clear. One possibility is that they are directly 
produced in blood during S. aureus bacteremia. However, several studies demonstrated that 
hemoglobin peptides inhibit superantigen production by S. aureus (99, 100) and therefore, they 
likely disseminate systemically from focal sites of infection rather than being synthesized in the 
bloodstream by the bacteria (9). The anterior nares are known to be the most common 
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colonization site of S. aureus, which can be attributed to the route of transmission: S. aureus is 
commonly transferred from various surfaces by hands to the nasal niche via “nose picking” (11). 
Nasal carriage of S. aureus and particularly MRSA was shown to increase the risk of acquiring 
an infection with this pathogen 4-fold (101-103). Thus, inhalation of S. aureus enterotoxin may 
closely resemble the route of dissemination in humans. In fact, several reports of accidental 
exposure to aerosolized S. aureus enterotoxin in humans showed systemic symptoms of chills, 
headache, fever, myalgia, cough, dyspnea, vomiting and diarrhea (104).  
In mice, S. aureus enterotoxin inhalation initiates an inflammatory cascade through 
systemic activation of specific T cells, accompanied by a robust cytokine release into circulation, 
including, IL-6, TNF or IFNγ. In addition to the systemic changes, S. aureus enterotoxin-specific 
αβ T cells in the lung induce IL-17 release by γδ T cells, which aids recruitment of neutrophils 
into the airways. This early systemic inflammatory response occurs within several hours after 
inhalation. By 48 h, S. aureus enterotoxin-specific T cells expand in all lymphoid tissues as well 
as the lung. The increased protein concentration and cell number in the BAL fluid (particularly, 
innate cells, NK cells and T cells) are indicative of pulmonary injury. Histologically, the lung 
tissue showed perivascular and peribronchial inflammation, disruption of terminal vessels, and 
accumulation of red blood cells, leukocytes and proteins (30, 34, 39, 105, 106). Although these 
studies highlighted key features of S. aureus enterotoxin-induced inflammation, there are many 
remaining questions. In particular, it is not known how S. aureus enterotoxin spreads 
systemically following inhalation, what is the crosstalk between the adaptive immune system 
and innate cells and how S. aureus enterotoxin drives lung injury and increased vascular 
permeability. The following studies investigate the mechanisms of systemic and pulmonary 
immune responses after SEA inhalation. 
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FIGURE 1.1: Diagram of general processes involved in sepsis. Sepsis can be triggered by a 
number of inflammatory stimuli, such as pneumonia, trauma, or surgery. The inflammatory 
trigger induces an overwhelming immune response (e.g. through pattern recognition receptors), 
particularly involving innate immune cells: neutrophils, monocytes and macrophages (MΦs). 
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Recent evidence suggests that T cells (particularly through superantigen-induced activation) 
may also play a critical role in the pathogenesis of sepsis. The activated immune cells release 
pro-inflammatory factors, cytokines and chemokines, which further activate platelets and the 
complement system. The resulting response triggers a state of hyperinflammation known as 
systemic inflammatory response syndrome (SIRS), which may be counterbalanced by a state of 
immunosuppression known as compensatory anti-inflammatory response syndrome (CARS). As 
a consequence of the increased inflammation, tissue and vasculature become injured due to 
oxidative stress, hypoperfusion, and disseminated intravascular coagulation (DIC). Multiple 
organs can be affected, including lung or kidney (multi-organ dysfunction syndrome; MODS). 
The vascular injury leads to hypotension, which if refractory to fluids is known as septic shock.  
 
 
Group 
Low affinity 
binding to α chain 
of MHC II 
High affinity 
binding to β chain 
of MHC II 
Presence 
of cystine 
loop 
Representative 
superantigens 
I ✔ ✖ ✖ TSST-1, SE-l X 
II ✔ ✖ ✔ 
SEB, SEC, SEG, SE-l 
U, SE-l W, SPE A, 
SSA 
III ✔ ✔ ✔ 
SEA, SED, SEE, SE-l 
H, SE-l J, SE-l N to 
SE-l P 
IV ✔ ✔ ✖ 
SPE C, SPE G, SPE 
J, SMEZ 
V ✔ ✔ ✖ 
SE-l I, SE-l K to SE-l 
M, SE-l Q to SE-l T, 
SE-l V, SPE H 
 
TABLE 1.1: Categorization of superantigens. The table represents categorization of 
staphylococcal and streptococcal superantigens based on their structural properties. TSST-1 = 
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toxic shock syndrome toxin-1, SE = staphylococcal enterotoxin, SE-l = staphylococcal 
enterotoxin-like protein, SPE = streptococcal pyrogenic exotoxin, SSA = streptococcal 
superantigen, SMEZ = streptococcal mitogenic exotoxin Z. Adapted from Spaulding et al. (9). 
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Chapter 2: Materials and Methods 
 
Mice 
C57BL/6J (WT), MHC II−/−, and TCR βδ−/− mice were obtained from Jackson Laboratory (Bar 
Harbor, Maine). CD169-DTR mice were a kind gift from Dr. Kamal M. Khanna (UConn Health, 
Department of Immunology, Farmington, CT). Mice were used between 1.5 and 4 months of 
age. All mice were kept in the Central Animal Facility at UConn Health in accordance with 
federal guidelines. All experimental procedures were approved by the Institutional Animal Care 
and Use Committee of UConn Health. 
 
Toxin administration 
To administer SEA, mice were anesthetized with isoflurane (Phoenix, St. Joseph, MO) in a 
vaporing chamber (Midmark, Versailles, OH). In most studies, 1 µg of SEA (Toxin Technology, 
Sarasota, FL) diluted in 50 µL of balanced salt solution (BSS) or BSS alone  (vehicle) was 
pipetted on the nostrils (intranasal route – i.n.). In SEA titration experiments, 0.033 µg, 0.1 µg, 
0.33 µg or 1 µg of SEA was administered i.n. as described before. The mice recovered from the 
anesthesia immediately after inhaling the toxin or vehicle control.  
To ablate CD169+ cells in CD169-diphteria toxin receptor (DTR) mice, mice received 40 ng/g of 
body weight of diphtheria toxin (DT; Sigma-Aldrich) intraperitoneally  (i.p.) 2 days before SEA or 
vehicle inhalation. Flow cytometry of the lung tissue was used to confirm cell depletion 2 days 
following DT injection.  
 
Adoptive transfer 
To adoptively transfer T cells, spleen and peripheral LNs (axillary, brachial, and inguinal) were 
collected from naïve WT mice. The tissue was passed through 100-µm strainer (Falcon/BD 
Biosciences) and RBCs were lysed with an ammonium chloride solution. The single cell 
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suspension was washed, re-suspended in 3 mL of BSS and then pipetted onto a nylon wool 
column. The column was then incubated at 37°C for 30 min. This step was repeated after 
pushing 3 mL of BSS through the column. The column was then flushed with BSS and the 
enriched cells were counted using Z1 particle counter (Beckman Coulter, Brea, CA). The purity 
of the cells was determined by flow cytometry (FACS LSRII; BD Biosciences). After 
anesthetizing mice with ketamine/xylazine solution (10 mg/mL of ketamine, 0.5 mg/mL of 
xylazine in PBS injected i.p. as 10µL/g of body weight), enriched T cells (~3.5×106 T cells) were 
adoptively transferred into TCR βδ-/- recipient mice by retro-orbital injection as previously 
reported (30, 39).  
 
In vivo antibody neutralization 
For neutralization therapy experiments, mice received an i.p. injection of the following agents 
diluted in PBS:  
TABLE 2-1: Antibodies used in vivo. 
Antibody Clone Dose Isotype control 
used 
Source 
Anti-4-1BBL TKS-1 200 µg Rat IgG2a BioXCell, Lebanon, 
NH 
Anti-CD40L MR1 500 µg Hamster IgG BioXCell 
Anti-CD54 YN1/1.7.4 500 µg Rat IgG BioXCell 
Anti-CD178 101626 250 µg Rat IgG R&D Systems, 
Minneapolis, MN 
Anti-TNF XT3.11 500 µg Rat IgG BioXCell 
CTLA4-Ig* N/A 200 µg Mouse IgG Dr. Robert Mittler 
(Department of 
Surgery and Emory 
Vaccine Center, 
Emory University, 
Atlanta, GA). 
CTLA4-Ig** N/A 250 µg Rat IgG Sigma-Aldrich, St. 
Louis, MO 
*  Used in experiments in chapter 1 
** Used in experiments in chapter 2 
 
 	 18	
Mouse IgG was from Sigma-Aldrich. Other isotype controls were obtained from BioXCell. All 
antibodies except anti-CD54 and anti-CD178 were administered 2 h prior to SEA inhalation. 
Anti-CD54 and anti-CD178 were given 36 h after SEA inhalation.  
 
In vivo permeability assays 
The in vivo permeability assays were performed using FITC-dextran similarly as described 
before (107, 108). To assess lung permeability from lung to blood, mice received 50 µL of FITC-
dextran (3000 mW; 5 mg/mL; Life Technologies) i.n. and serum from tail blood was obtained 1 h 
later. For blood into lung permeability assay, mice received 100 µL of FITC-dextran i.v. through 
the retro-orbital route and BAL fluid was collected 1 h later. FITC fluorescence in the serum 
(1:70) or BAL fluid (undiluted) was determined by a plate reader (483-14/530-30; CLARIOstar, 
BMG LABTECH) and normalized either to the vehicle only-treated mice (Fig. 4-1) or the IgG-
treated mice (Fig. 4-8).  
 
Pan-caspase imaging 
The amount of apoptosis in lung and spleen was detected by CAS-MAPTM near-infrared in vivo 
fluorescent imaging probe (Vergent Bioscience, Minneapolis, MN) according to the 
manufacturer’s instructions. Briefly, the by CAS-MAPTM probe was i.v. injected 60-90 min prior 
to sacrifice. Lung and spleen were then imaged by Odyssey CLx Imager (LI-COR, Lincoln, NE). 
 
Tissue harvest and processing 
LNs and spleen  
Airway-draining (mediastinal and cervical) and airway-non-draining LNs (axillary, brachial, 
inguinal and mesenteric) were harvested. LNs and spleen were crushed and passed through a 
100-µm strainer (Falcon/BD Biosciences). RBCs were lysed with ammonium chloride solution. 
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BM 
BM was flushed out with a 10 mL-syringe filled with BSS from one femur and tibia until no 
remaining tissue was observed. The tissue was passed through a 100-µm strainer and RBCs 
were lysed. 
Peripheral blood 
Mice were warmed up with a heat lamp for 3 min and peripheral blood was obtained by making 
a small incision on their tail. For serum, the blood was collected into serum separator tubes (BD 
Biosciences). For blood cells, 3-4 drops of blood were collected into BSS-heparin solution 
(0.411g/L; Sigma-Aldrich). The cells were washed and RBCs were lysed with ammonium 
chloride solution. This step was repeated to remove remaining RBCs.  
Lung 
Mice were sacrificed with an i.p. injection of ketamine. The lung tissue was perfused with PBS 
by inserting a butterfly needle through the heart. Alternatively, in experiments in which BAL fluid 
was collected, lung tissue was harvested without perfusion. The tissue was then dissected into 
small pieces, placed in a conical flask containing 20 mL of collagenase solution (150 U/mL 
collagenase (Sigma-Aldrich), 60 U/mL DNAse I (Sigma-Aldrich), 2% FBS, 1 mM Ca2Cl, 1 mM 
Mg2Cl), and left spinning at 230 rpm for 30 min at 37°C. The tissue was passed through a 100-
µm strainer and RBCs were lysed with ammonium chloride solution and counted. 
BAL fluid 
The mice were sacrificed with an i.p. injection of ketamine. The thoracic cavity was exposed and 
a small incision was made into the upper portion of the trachea. A syringe containing 2 mL of 
PBS attached to polyethylene tubing (0.58x0.97 mm; Instech Laboratories, Inc., Plymouth 
Meeting, PA) was inserted into the trachea and secured with a thread. The lungs were then 
gently lavaged by injecting PBS into the tissue until fully expanded. The lavage was repeated 2-
3 more times. 
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Flow cytometry 
Surface staining for flow cytometry was performed as described previously (30). Single cell 
suspensions were counted with Z1 particle counter (Beckman Coulter, Brea, CA). Unspecific 
binding was blocked with FcR blocking solution (culture supernatant from 2.4.G.2 hybridoma, 
5% mouse serum (Sigma-Aldrich), 10 µg/mL human IgG (Sigma-Aldrich), 0.1% sodium azide) 
and stained with antibodies and LIVE/DEAD® Fixable Blue Dead Cell Stain (Life Technologies, 
Grand Island, NY) for 30-45 min on ice. For intracellular staining, cells were cultured with 
brefeldin A (1 µg/mL; Calbiochem, San Diego, CA) and with or without PMA (50 ng/mL, 
Calbiochem)/ ionomycin (1 µg/mL, Fisher Scientific) for 5 h. The cells were stained with surface 
antibodies, fixed in 2% formaldehyde, permeabilized with 0.25% saponin and stained with 
intracellular antibodies overnight at 4°C. Flow cytometry was performed using a FACS-LSRII 
(BD Biosciences) and the data was analyzed with FlowJo software (Tree Star, Ashland, OR).  
Antibody-stained positive cells were determined with corresponding isotype controls. 
Fluorochrome-conjugated antibodies were obtained from BD Biosciences (San Jose, CA), 
eBioscience (San Diego, CA), or BioLegend (San Diego, CA). The following fluorochrome-
conjugated antibodies were used: 
TABLE 2-2: Flow cytometry antibodies and the clones. 
Antibody Clone 
anti-CD3 145-2C11 or 
17A2 
anti-CD19 1D3 
anti-CD8a 53-6.7 
anti-B220 RA3-6B2 
anti-NK1.1 PK136 
anti-CD49b DX5 
anti-Ly6G 1A8 
anti-Ly6C HK1.4 
anti-CD11c HL3 or N418 
anti-Vβ3 KJ25 
anti-Vβ14 14-2 
anti-CD25  PC61 
anti-CD69 H1.2F3 
anti-MHC II M5/114.15.2 
anti-F4/80 BM8 
anti-CD103 2E7 
anti-CD11b M1/70 
ant-CD45.2 
(shown as 
CD45) 
104 
anti-CD31 390 
anti-CD54 YN1/1.7.4 
anti-
granzyme  B 
NGZB 
anti-CD95 Jo2 
anti-CD11a H155-78 
anti-IFN-γ XMG1.2 
anti-SIGLEC 
F 
E50-2440 
anti-CD169 SER-4 
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Staining for SEA was performed with polyclonal anti-SEA antibody produced in rabbit (whole 
antiserum; Sigma-Aldrich) followed by secondary rabbit IgG Alexa Fluor 488 (Life 
Technologies).
 
Cell sorting 
For T cell sorting, LNs (cervical, mediastinal, axillary, brachial, inguinal, and mesenteric) 
were collected and processed as described above. For sorting of dendritic cells (DCs), the 
LN tissue was digested with collagenase solution (150 U/mL collagenase (Sigma-Aldrich), 
2% FBS in MEM) for 30 min at 37°C and 5% CO2. After tissue digestion, 100 µL of 0.1M 
EDTA in PBS per 1 mL of collagenase solution was added. The tissue was then passed 
through a 100-µm strainer and washed in 5 mM EDTA and 2% FBS Ca2+/Mg2+ free BSS. For 
endothelial cell sorting, lung tissue was prepared as described above. After FcR blocking 
and antibody staining, cells were sorted with FACS Aria (BD Biosciences).  
 
CyTOF 
Lungs were obtained from mice 14 or 40 h after SEA or vehicle inhalation, digested with 
collagenase/DNAse solution and purified using Lympholyte M (Cedarlane Labs, Burlington, 
NC). Each one of the 4 samples was labeled with Cell-IDTM Cisplatin to identify live and 
dead cells and subsequently barcoded with Cell-IDTM Pd Barcoding kit (all CyTOF reagents 
are from Fluidigm, San Francisco, CA). The 4 samples were pooled together, permeabilized 
with methanol, and incubated with Fc receptor blocking solution and 24 heavy metal-
conjugated antibodies, including 7 signaling markers. DNA was labeled using Cell-IDTM 
Intercalator-Ir. The pooled sample was spiked with normalization beads and analyzed by a 
mass cytometer (Helios, Fluidigm). The data were de-barcoded using the Fluidigm 
Debarcoder v1.04. A single cell and live cell gate were obtained from each sample. The 
samples were further sub-gated to include the same number of cells per sample and 
merged to create ViSNE maps (MATLAB, MathWorks, Natick, MA) using only the non-
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signaling markers. Histograms comparing the expression of signaling and activation markers 
were generated using MATLAB. Median intensity values were obtained by FlowJo software.  
 
Co-culture assays 
To obtain naïve T cells, spleen and LNs were harvested from a naïve mouse and processed 
as described above. To enrich the population of Vβ3+ T cells, the cells were depleted using 
anti-B220 clone RA3-6B2, anti-NK1.1 clone PK136, anti-Vβ2 clone B20.6, anti-Vβ4 clone 
KT-4, anti-Vβ5.1,5.2 clone MR9-4, anti-V6β clone RR4-7 and anti-Vβ8 clone F23.1 biotin-
conjugated antibodies (eBioscience and BD Biosciences) and anti-biotin magnetic beads 
(Miltenyi Biotec Inc, Auburn, CA). For co-culture of T cells with serum or blood cells, tail 
blood was obtained 10 or 30 min after SEA or vehicle inhalation into either heparin-
containing BSS or serum separator tubes (BD Biosciences). Blood cells were processed as 
described above. Next, the enriched T cells (100,000/well) were incubated with either cells 
derived from the blood (25,000/well) or the isolated serum (diluted 1:4 in culture medium) 
overnight at 37°C and 5% CO2. For co-culture of T cells with DC subpopulations, LNs 
(mediastinal, cervical, axillary, brachial, inguinal) were collected 40 min after SEA or vehicle 
inhalation and processed as described above. The cells were enriched for DCs by depleting 
B220+ and Thy1.2+ cells using Dynabeads (Life Technologies), stained and sorted. The 
sorted DC subpopulations (5,000/well) were incubated with naïve enriched T cells 
(20,000/well) overnight at 37°C and 5% CO2. After the culture, supernatants were collected 
to measure IL-2 concentration by ELISA (BD Biosciences) and the cells were washed and 
stained for flow cytometry as described above.  
 
ELISA and multiplex assays 
Serum was obtained from tail blood by using the serum separator tubes (BD Biosciences). 
BAL fluid was collected as described above. The isolated serum and BAL fluid were stored 
at −80°C. ELISAs for albumin (Bethyl Laboratories, Montgomery, TX), CD54, angiopoietin-2, 
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receptor for advanced glycation end products (RAGE), granzyme B (R&D Systems) and 
cytokine ELISAs for IL-6, TNF and IFN-γ (BD Biosciences) were performed according to the 
manufacturer’s instructions. 
For the multiplex assay of LN lysates (see chapter 3), LNs were isolated from mice 4 or 16 h 
after SEA or vehicle exposure. The tissue was placed in MagNA Lyser green beads tubes 
(Roche, Basel, Switzerland) filled with 400 µL PBS containing Protease Inhibitor Cocktail 
(Sigma-Aldrich) and lysed using MagNA Lyser Instrument (Roche) at 6,000 rpm for 1 min. 
The lysates were stored in −80°C. Chemokine and cytokine expressions were measured 
with customized Luminex® -based multiplex assay (EMD Millipore, Billerica, MA). The 
expression of individual chemokines and cytokines was normalized to the protein 
concentration measured by the Pierce BCA protein assay kit (Thermo Scientific, Rockford, 
IL). Bio-Plex Pro™ Mouse Cytokine 23-plex Assay (Biorad) was used to measure the time 
course of cytokine and chemokine release in serum and BAL fluid (see chapter 4). 
 
Quantitative real-time PCR and RNA sequencing 
For quantitative real-time PCR (qRT-PCR) analyses of the whole tissue, LNs from SEA or 
vehicle-exposed mice were removed, frozen on dry ice and stored at −80°C. To acquire 
RNA, the whole tissue was snap-frozen in liquid nitrogen and crushed into powder. The total 
RNA was isolated from the LN tissue or sorted cells with RNeasy Mini Kit (Qiagen, Valencia, 
CA) and converted to cDNA using iScript cDNA Synthesis Kit (Biorad, Hercules, CA). mRNA 
expression level of target genes and the endogenous control gene β-actin or Gapdh were 
assessed by real-time PCR using Taqman primers (Life Technologies) and a CFX96 Real-
Time PCR instrument (Biorad). Each sample was run in duplicate and the gene expression 
was normalized to β-actin or Gapdh using the standard curve method.  
 
For RNA sequencing, total LN cells (isolated from cervical, mediastinal, axillary, brachial, 
inguinal, and mesenteric LNs) were collected 40 min after SEA or vehicle inhalation. The 
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cells were sorted and mRNA was acquired as described above. Total RNA was sequenced 
(Otogenetics, Norcross, GA) and transcriptomes from SEA Vβ3+ T cells were compared to 
transcriptomes from vehicle Vβ3+ T cells and SEA Vβ14+ T cells (control groups). Genes in 
SEA Vβ3+ cells that were downregulated (log2 fold change ≤ −1.5) or upregulated (log2 fold 
change ≥ +1.5) were compared to control groups in all three experiments were selected. 
The selected list of genes was further examined and any genes with inconsistent or close to 
zero expressions removed. Gene expressions patterns in the selected genes were analyzed 
using Gene set enrichment analysis (GSEA, Broad Institute, Cambridge, MA). The following 
gene set databases were used: h.all.v5.0.symbols.gmt and c5.all.v5.0.symbols.gmt 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp). To construct heat maps, gene 
expressions were corrected to log2 and processed using GENE-E software (Broad Institute). 
The RNA sequencing data can be viewed online (http://www.ncbi.nlm.nih.gov/geo/; 
accession number: GSE76190). 
Confocal microscopy 
Whole cervical LNs or lung was fixed in periodate-lysine-paraformaldehyde (PLP) solution (1 
µM sodium periodate, 75 mM L-lysine, 1% paraformaldehyde in phosphate buffer) at 4°C 
overnight. The tissue was washed in phosphate buffer, left in 30% sucrose at 4°C overnight, 
frozen in OCT and stored at −80°C. The frozen tissue was cut into 20 µm-thick sections with 
LEICA CM1850 cryostat (Leica Biosystems, Buffalo Grove, IL) and the sections were stored 
at −20°C. For antibody staining, the sections were firstly blocked for unspecific binding using 
a staining buffer (either 2% FBS in PBS or 2% FBS, 2% goat serum, 0.5% FcR blocking 
solution, 0.05% Tween-20, 0.3% Tritone-X100 in PBS) for 1 h at RT and then stained with 
primary antibodies diluted in the staining buffer for 1 h at RT. The sections were examined 
with Zeiss LSM780 confocal microscope mounted on an inverted Axio Observer Z1 (Zeiss, 
Oberkochen, Germany). Immunofluorescent staining was performed with the following 
antibodies: DyLight 488-conjugated anti-Ly6B.2 clone 7/4 (labeled as 7/4; Novus 
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Biologicals, Littleton, CO), V450-conjugated anti-CD11b clone M1/70, PE-conjugated anti-
Vβ3 clone KJ25, allophycocyanin-conjugated anti-CD11c clone HL3, PE-conjugated anti-
active caspase-3 clone C92-605 (all from BD Biosciences), eFlour 660-conjugated anti-
CD169 clone SER-4, allophycocyanin-conjugated MHC II clone M5/114.15.2 ( both from 
eBioscience). SEA staining was performed with polyclonal anti-SEA antibody (whole rabbit 
antiserum; Sigma-Aldrich) followed by Alexa Flour 488-conjugated anti-rabbit IgG staining. B 
cell follicles in LNs were determined with Pacitic Orange-conjugated anti-B220 clone RA3-
6B2 (not shown in images; Life Technologies). The images represent confocal z-stack 
projections, which were acquired using 20×/0.8 numerical aperture objective. Image 
analysis, including adjustment for contrast and brightness and cellular quantification, was 
done with Imaris software (Bitplane, Zurich, Switzerland). The number of active caspase-3+ 
cells in the SEA-exposed mice was only determined in loci of increased inflammation (areas 
with an increased number of inflammatory cells). No such areas were found in the vehicle 
control. Colocalization studies that measured the percentage of cells positive for multiple 
markers were completed by Imaris with threshold value for colocalization set to 7.  
 
Statistical analysis 
The following tests were used to determine statistical significance (p<0.05): one-way 
ANOVA (with Dunnett’s or Tukey’s multiple comparisons tests), two-way ANOVA (with 
Sidak’s multiple comparisons test), two-tailed Student’s unpaired t test or paired t test. All 
statistical tests were performed using Prism-GraphPad (La Jolla, CA) and Microsoft Excel.  
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Chapter 3: Systemic Inflammatory Response Following S. aureus Enterotoxin 
A Inhalation 
 
This work was published in the Journal of Immunology, vol. 196, issue 11, pp. 4510-4521, 
June 1, 2016 under the title “TNF and CD28 Signaling Play Unique but Complementary 
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Enterotoxin A Inhalation” and was authored by: Julia Svedova, Naomi Tsurutani, Wenhai 
Liu, Kamal M. Khanna, and Anthony T. Vella. 
Some modifications to the original text were done to accommodate additional figures and 
tables used to supplement this chapter. 
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Abstract 
 
Staphylococcus aureus enterotoxins cause debilitating systemic inflammatory responses, 
but how they spread systemically and trigger inflammatory cascade is unclear. Here, we 
showed in mice that after inhalation, Staphylococcus aureus enterotoxin A rapidly entered 
the bloodstream and induced T cells to orchestrate systemic recruitment of inflammatory 
monocytes and neutrophils. To study the mechanism used by specific T cells that mediate 
this process, a systems approach revealed inducible and non-inducible pathways as 
potential targets. It was found that TNF caused neutrophil entry into the peripheral blood, 
while CD28 signaling, but not TNF, was needed for chemotaxis of inflammatory monocytes 
into blood and lymphoid tissue. However, both pathways triggered local recruitment of 
neutrophils into lymph nodes. Thus, our findings revealed a dual mechanism of monocyte 
and neutrophil recruitment by T cells relying on overlapping and non-overlapping roles for 
the non-inducible costimulatory receptor CD28 and the inflammatory cytokine TNF. During 
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sepsis, there might be clinical value in inhibiting CD28 signaling to decrease T cell-mediated 
inflammation and recruitment of innate cells while retaining bioactive TNF to foster 
neutrophil circulation. 
 
Introduction 
 
Staphylococcus aureus (S. aureus) is a part of normal human flora colonizing skin, 
nasopharynx and most commonly the anterior nares of the nose in almost 30% of the 
general population (11). A recent epidemiological study showed that Gram-positive bacteria 
were found in 47% of intensive care unit patients with an infection, with S. aureus present in 
20% of positive cultures (77). Infection and related sepsis are one of the leading causes of 
death in the United States (3). Sepsis, characterized as systemic inflammatory response 
syndrome (SIRS) with a known or suspected infection, is a result of a dysregulated immune 
response, commonly accompanied by an uncontrolled release of cytokines that can lead to 
systemic tissue injury, shock and even death (7). Methicillin-resistant S. aureus is 
particularly well spread in hospital settings and is associated with key virulence factors that 
may contribute to the severity and rapidity of sepsis (13). One such virulence factor is 
superantigens, such as S. aureus enterotoxins. These are heat resistant proteins that 
bypass classical antigen processing and presentation to mediate powerful oligoclonal T cell 
receptor Vβ chain-specific responses (110, 111) leading to toxic shock syndrome and 
potentially death (32, 112-114). 
A recent study showed that the presence of an enterotoxin was essential for the 
lethality of S. aureus-induced sepsis in rabbits (85). In addition, superantigens can synergize 
with TLR4 or TLR2 agonists and enhance the inflammatory response and the induction of 
lethal shock in mice (115, 116). Superantigens have been found in blood of septic patients 
and their prevalence, in particular prevalence of S. aureus enterotoxin A (SEA), was 
correlated with severity of infection (79, 80, 117). Therefore, it is likely that the presence of 
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S. aureus enterotoxins drives or at least significantly exacerbates the inflammatory response 
in septic patients. It is still unclear, however, how S. aureus enterotoxins spread systemically 
especially in cases of an unknown entry point and how they trigger both adaptive and innate 
immunity to propagate systemic inflammation.    
Mice exposed to S. aureus enterotoxins reproduce several important hallmarks of 
SIRS/sepsis in humans, including a rapid-onset immune response with a robust cytokine 
release (10, 111) and an immunosuppression/anergy phase (52, 118, 119) similar to the 
compensatory anti-inflammatory response syndrome (CARS) that often occurs in septic 
patients (120). Furthermore, SEA inhalation also recapitulates a common complication in 
sepsis, acute lung injury.  The lungs of exposed mice show elevated proteins, presence of 
red blood cells and increased levels of cytokines (39, 106). Using the SEA model of SIRS, 
we sought to study systemic immune responses occurring immediately after SEA 
administration. The pulmonary SEA challenge resulted in a rapid release of monocytes and 
neutrophils to blood and their accumulation in lymphoid tissues. Remarkably, this 
inflammatory innate cell migration was dependent on the presence of T cells. In particular, 
the systemic recruitment of monocytes and neutrophils was dually regulated by T-cell based 
CD28 signaling and the inflammatory cytokine TNF. 
 
Results 
 
Systemic recruitment of monocytes and neutrophils is observed rapidly after SEA 
inhalation 
SEA inhalation results in alveolitis characterized by increased protein content, 
presence of RBCs, secretion of cytokines, and accumulation of monocytes and neutrophils 
(30, 39). The local lung response is coincident with an expansion of SEA-specific T cells in 
all lymphoid tissues (39). To understand how SEA inhalation causes a systemic response, 
serum and blood cells were isolated immediately after SEA or vehicle challenge and 
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incubated with enriched naïve T cells. Cells derived from blood after SEA or vehicle 
inhalation and serum from vehicle mice did not affect T cell activation (Fig. 3-1, A and B; 
data not shown). However, serum obtained only 10 min after SEA inhalation was able to 
activate SEA-specific Vβ3+ T cells to express CD69 and CD25 while having little effect on 
bystander Vβ14+ T cells (Fig. 3-1, A and B). The same type of response was observed when 
the naïve T cells were incubated with SEA (Fig. 3-2). Finally, only T cells co-cultured with 
serum from SEA mice produced IL-2 (Fig. 3-1, C). To estimate the amount of SEA that was 
found in the serum upon inhalation, enriched naïve T cells were co-cultured with increasing 
concentrations of SEA overnight and the level of T cell activation was assessed by flow 
cytometry. Fig. 3-2 represents titration curves of CD69 and CD25 expression on SEA-
specific Vβ3+ T cells and bystander Vβ14+ T cells. The titration curves were then used to 
extrapolate the concentration of SEA in the serum of mice 10 min after SEA inhalation 
(dotted line – value obtained from Fig. 1A and B). Because the serum was diluted 1:4 when 
added to culture, the concentration of SEA in the serum was estimated to be between ~12 
and 28 ng/mL of blood (Fig. 3-2; red arrow values multiplied by 4). Interestingly, this 
concentration was only a fraction of the amount administered i.n. to each mouse (1 µg). 
Thus, SEA can rapidly enter the bloodstream after inhalation in small but sufficient quantities 
to activate T cells.   
The rapid spread of the enterotoxin after inhalation through blood posed the question 
of whether the systemic inflammatory response to SEA was accompanied by a common 
hallmark of SIRS and sepsis, blood leukocytosis (7). To test if SEA inhalation mediates 
systemic circulation of innate immune cells, mice were challenged with SEA or vehicle alone 
and then the peripheral blood cells were analyzed for the presence of monocytes or 
neutrophils. Inflammatory monocytes were identified as CD3−CD19−CD11b+Ly6G-Ly6Chi 
while neutrophils were identified as CD3−CD19−CD11b+Ly6G+Ly6C+ (Fig. 3-3, A). The 
percent of neutrophils in blood increased 6.4-fold 2 h after SEA challenge compared to 
vehicle while there was no relative increase in monocytes (Fig. 3-3, B). Nevertheless, both 
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populations were increased 4 h after SEA inhalation. SEA-based inflammation is dependent 
on T cells, which are found in lymphoid tissues (39). Therefore, it was hypothesized that the 
circulating inflammatory innate cells would migrate to the LNs and spleen. Indeed, the 
percent of inflammatory monocytes and neutrophils at 4 h after SEA inhalation was 
increased in spleen, mediastinal, cervical, and non-draining LNs compared to vehicle control 
(Fig. 3-3, C). Inflammatory monocytes remained elevated at 12 h whereas the percent of 
neutrophils decreased to the level of vehicle-treated mice. Like percentages, the same 
trends were observed when assessing the absolute numbers of inflammatory monocytes 
and neutrophils (data not shown). The recruited monocytes likely originated from the BM 
because there was a depletion of BM inflammatory monocytes reaching over 50% reduction 
compared to the vehicle control by 4 h after SEA inhalation (Fig. 3-3, D). Interestingly, SEA 
challenge caused only a small decline in the number of BM neutrophils. In sum, SEA 
inhalation resulted in rapid systemic recruitment of monocytes and neutrophils to blood and 
lymphoid tissues. 
 
The recruitment of innate immune cells after SEA inhalation is guided by T cells to the 
T cell zone of the LNs 
SEA inhalation induces monocyte and neutrophil migration to lungs in a T cell 
dependent manner (30). To determine the role of T cells in the systemic recruitment of 
innate immune cells to blood and LNs, TCR βδ−/− mice, that lack both αβ and γδ T cells, 
received C57BL/6J T cells or nothing and subsequently, they were i.n. challenged with SEA 
or vehicle. In the absence of T cell transfer, cervical LNs and blood from SEA-treated mice 
showed no difference in accumulation of monocytes or neutrophils compared to the vehicle 
group (Fig. 3-4). However, SEA-challenged TCR βδ−/− mice that received T cells had 
significant increases in the percent of both monocytes and neutrophils compared to vehicle 
alone (Fig. 3-4). Thus, T cells were required to trigger the systemic recruitment of 
inflammatory innate immune cells to blood and LNs after inhalation of SEA.  
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Migration of neutrophils and monocytes to LNs was previously reported (121-127). 
However, while some studies showed that following an infection or antigen challenge, 
neutrophils were recruited to the subcapsular sinus (121, 124), others found innate immune 
cells in the T cell zone (125, 127). To determine where the recruited cells accumulated, 
cervical LNs were collected 1, 2, and 4 h after SEA inhalation and examined by confocal 
microscopy. Inflammatory innate immune cells (CD11b+7/4+) were detected in the LNs as 
early as 2 h after SEA but not in the vehicle control (Fig. 3-5, A). By 4 h, the quantity of 
inflammatory innate immune cells increased even further, which was confirmed by 
enumerating 7/4+ cells per field (Fig. 3-5, B). Importantly, the recruited cells were primarily in 
the T cell zone of the LNs whereas the few inflammatory cells in the vehicle alone mice were 
mostly located in the subcapsular sinus and B cell follicles (Fig. 3-5, C). These findings 
demonstrate that SEA inhalation induced recruitment of monocytes and neutrophils 
particularly to the T cell zone in the LNs where the SEA-specific T cells become activated. 
 
SEA inhalation triggers a rapid release of specific chemokines by both T cells and 
dendritic cells 
Monocyte and neutrophil migration can be driven by a number of chemokines (128-
130). To understand which chemotactic factors might play a role in the systemic recruitment 
of monocytes and neutrophils, total RNA was isolated from draining LNs (cervical and 
mediastinal) to assess the expression of various chemokine genes. Compared to vehicle, 
expression of multiple chemotactic factors increased as early as 1 h after SEA inhalation 
(Suppl. Fig. 2A). Interestingly, mRNA levels of chemokines particularly important for the 
recruitment of neutrophils and monocytes – Cxcl1, Cxcl2, Ccl2, Ccl3, Ccl4, and Ccl7 (128, 
130) showed a rapid increase in expression peaking at 2 h (Fig. 3-6, A; clear bar graphs). 
To validate these findings, LN lysates were examined for the protein levels of these 
chemokines by a multiplex assay. Multiple chemokines were significantly elevated 4 h after 
SEA inhalation, including 38-fold for CXCL1, 792-fold for CXCL2, 53-fold for CCL2, 46-fold 
 	 32	
for CCL3 and 92-fold for CCL4 (Fig. 3-6. B). Nevertheless, the increased chemokine levels 
were transient because by 16 h after SEA challenge, they were already decreasing. In 
addition, the expression of chemotactic factors was systemic as SEA challenge caused a 
similar increase in chemokine levels in draining LNs, peripheral LNs, and mesenteric LNs 
(data not shown). We previously showed that SEA-activated αβ T cells directed γδ T cells to 
release IL-17, which contributed to the recruitment of neutrophils to lungs after SEA 
inhalation (30). Therefore, we assayed for IL-17, but only a small increase was detected in 
the LN lysates of the SEA group compared to vehicle (Fig. 3-6, B, bottom panel).  
Because SEA can directly crosslink MHC class II (MHC II) molecules on antigen-
presenting cells and Vβ chains of the TCR (22), we hypothesized that DCs and T cells were 
an important source of chemokines recruiting monocytes and neutrophils. Therefore, 
Lin−CD11c+MHC II+ DCs were sorted and the relative expression of chemokines was 
determined. DCs from SEA-challenged mice upregulated Cxcl1 and Cxcl2 mRNA levels but 
not Ccl3 and Ccl4 compared to DCs from the vehicle group (Fig. 3-7, A). Interestingly, SEA-
activated Vβ3+ T cells but not bystander Vβ14+ T cells substantially expressed Ccl3 and 
Ccl4, in particular, 680-fold and 738-fold increases compared to vehicle, respectively (Fig. 3-
7, B). DCs are heterogeneous and thus, to understand if a specific subset was critical, 
CD11clowMHC IIhi migratory DCs and CD11chiMHC IIlow resident DCs (131, 132) were sorted 
(Fig. 3-7, C). Migratory DCs expressed more Cxcl1 and Cxcl2 as normalized to β-actin 
expression than the resident DCs (Fig. 3-7, D). To summarize, SEA inhalation induced rapid 
production of chemokines by SEA-activated T cells and DCs (predominatly migratory DCs). 
To see if the differential chemokine expression in the DC subpopulations was due to 
their ability to present SEA, we tested if either migratory DC (Lin−CD11clowMHC IIhi) or 
resident DC (Lin−CD11chiMHC IIlow) subpopulations were preferentially stimulating the SEA-
specific T cells. In particular, four distinct DC subpopulations were sorted from either SEA or 
vehicle-immunized mice (Fig. 3-8, A) and without adding SEA, the sorted DC 
subpopulations were cultured with naïve T cells. Both CD11b+ and CD103+ migratory DCs 
 	 33	
from the SEA-immunized mice, but not resident DCs, activated Vβ3+ T cells to upregulate 
CD69 (Fig. 3-8, B). There was no difference in CD69 expression on the bystander Vβ14+ T 
cells when cultured with DCs from SEA-immunized mice compared to the vehicle control. 
These findings show that that only migratory DCs presented SEA ex vivo to naïve SEA-
specific T cells.  
 
Mechanism of T cell guided innate cell recruitment 
To determine the mechanism of how SEA-activated T cells promote chemokine 
production by DCs, SEA-specific Vβ3+ and bystander Vβ14+ T cells were sorted 40 min after 
SEA or vehicle inhalation and RNA was isolated for transcriptome analysis (Fig. 3-9, A). 
Comparing RNA from SEA Vβ3+ T cells to vehicle Vβ3+ or SEA Vβ14+ control groups, many 
genes were found to be upregulated in the SEA-specific Vβ3+ T cells (Fig. 3-9, B; Table 3-1). 
Gene expression increases were predominantly associated with cell development, 
proliferation, and regulation of metabolic processes. However, GSEA also revealed a 
significant association with apoptosis and negative regulation of cells (Fig. 3-9. C). In 
addition, both pro- (Tnf, Il2, Ifng) and anti-inflammatory cytokines (Il10) were upregulated in 
Vβ3+ T cells from the SEA-treated group suggesting a role for T cell costimulation (Fig. 3-9, 
D).  
The expression of inducible as well as constitutively expressed costimulatory 
molecules were compared. While there was no difference in the expression of constitutively 
expressed costimulatory molecules, five inducible costimulatory molecules were significantly 
upregulated in SEA Vβ3+ T cells, including 4-1BBL (Tnfsf9), LIGHT (Tnfsf14), CD40L 
(Cd40lg), SLAM (Slamf1), and TWEAK receptor (Tnfrsf12a) (Fig. 3-9, E and F). 
Interestingly, inducible coinhibitory molecules, particularly PD-L1 (Cd274), PD-L2 
(Pdcd1lg2), and PD1 (Pdcd1), were also upregulated in SEA Vβ3+ T cells compared to the 
control groups (Fig. 3-9, G and H), further confirming the dual capacity of T cells to promote 
and suppress inflammation immediately after SEA inhalation.  
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Previous studies found that 4-1BB-4-1BBL and CD40-CD40L pathways can enhance 
the recruitment of innate immune cells (133, 134). Furthermore, 4-1BBL and CD40L 
expression on Vβ3+ T cells was validated by flow cytometry (data not shown). Therefore, it 
was hypothesized that the systemic migration of innate immune cells might be dependent on 
the expression of inducible costimulatory molecules. To determine whether 4-1BBL and 
CD40L play a role in the migration of monocytes and neutrophils, mice were pre-treated with 
anti-4-1BBL, anti-CD40L or the corresponding IgG control and then i.n. challenged with 
SEA. Neither 4-1BBL nor CD40L blockade impeded migration of monocytes or neutrophils 
to blood and LNs (Fig. 3-10, A and B), suggesting other mechanisms were involved.  
One possibility is that a constitutively expressed costimulatory molecule, such as 
CD28, might be responsible for this recruitment. The membrane receptor CD28 engages its 
ligands CD80 and CD86 on DCs and potently enhances TCR-induced cytokine release and 
proliferation of naïve T cells (135, 136). In addition, CD28 engagement is needed for optimal 
superantigen-induced T cell expansion (137). Consistent with this previous work, genes 
associated with CD28 signaling (138-140) were upregulated in Vβ3+ T cells after SEA 
inhalation (Table 3-2). Secondly, cytokines like TNF and IL-2 are major factors released by 
enterotoxin-specific T cells (32, 141) and our data show that Tnf is promptly synthesized by 
SEA-specific Vβ3+ T cells (Fig. 3-9. D). Furthermore, GSEA of the hallmark pathways 
demonstrated a significant enrichment in the pathway of TNF signaling via NFκB in the SEA-
specific Vβ3+ T cells (Fig. 3-11, A). Thus, it was hypothesized that CD28 costimulation and a 
cytokine played redundant or non-overlapping roles in innate cell recruitment in SEA-
triggered acute inflammation. 
To test this notion, CD28 and TNF were neutralized in SEA-treated mice with 
CTLA4-Ig or anti-TNF. First, we tested whether CD28 or TNF neutralization affected serum 
IL-6 levels since increased IL-6 correlates with decreased survival not only in models of 
sepsis but also in septic patients (142-145).  Both, CTLA4-Ig and anti-TNF significantly 
reduced serum IL-6 compared to the IgG controls, with anti-TNF being even more effective 
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in decreasing IL-6 than CTLA4-Ig (Fig. 3-11, B). Thus, both treatments appeared to 
attenuate inflammation by reducing serum IL-6 levels. 
To assess whether CD28 or TNF orchestrate monocyte and neutrophil chemotaxis 
after SEA inhalation, LN tissue from CTLA4-Ig or anti-TNF treated-mice was examined for 
the expression of chemokines. While CTLA4-Ig significantly reduced Cxcl1, Cxcl2, Ccl2, 
Ccl3, and Ccl7 mRNA expression, anti-TNF only decreased Cxcl2 expression and had no 
significant effect on the other chemokines (Fig. 3-11, C). These findings suggested that 
CTLA4-Ig would be more effective in blocking the systemic recruitment of monocytes and 
neutrophils compared to anti-TNF. Indeed, the percent of inflammatory monocytes in LNs 
and blood was significantly reduced after CTLA4-Ig treatment. In contrast, anti-TNF 
relatively increased the percent of monocytes in the blood but had no effect on their 
migration to LNs (Fig. 3-11, D). Nevertheless, both CD28 and TNF blockade significantly 
reduced the accumulation of neutrophils in LNs (Fig. 3-11, E, upper panels). Based on the 
results from Fig. 3-3, B, which demonstrated robust migration of neutrophils and monocytes 
into the bloodstream after SEA inhalation, it was tested if these pathways operated by 
preventing migration of innate cells into blood. CTLA4-Ig did not inhibit neutrophil circulation 
(Fig. 3-11, E, lower left panel), but interestingly, TNF blockade significantly inhibited 
recruitment of neutrophils into blood (Fig. 3-11, E, lower right panel). These findings posed 
the question of whether the reduction of neutrophils in the LNs after anti-TNF treatment was 
due to the decreased circulation of blood neutrophils (Fig 1-11, E, lower panels) or reduced 
Cxcl2 expression (Fig. 3-11, C). In TNF blocked mice, there was no correlation between the 
percentage of neutrophils in the blood versus the LNs (Fig. 3-11, F). However, mRNA Cxcl2 
expression positively correlated with the percentage of neutrophils in the LNs suggesting 
that migration into LNs was dependent on a chemokine gradient rather than the amount of 
circulating cells (Fig. 3-11, G). Thus, the systemic recruitment of monocytes and neutrophils 
after SEA inhalation is orchestrated by a non-inducible CD28 signal with overlapping and 
non-overlapping roles for TNF.  
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Discussion 
 
Staphylococcus aureus enterotoxins have been implicated in the pathology of toxic 
shock, sepsis as well as a number of pulmonary and autoimmune diseases due to their 
ability to elicit a massive and systemic cytokine storm (10, 78, 95, 146). However, it is 
unclear how S. aureus enterotoxins enter the periphery to instigate these effects since the 
lungs and airways are usually impermeable to inhaled antigens. In fact, antigens are 
typically cleared from these tissues by a number of mechanisms, including mucociliary 
transport, innate defense molecules and resident phagocytes (147, 148). Alternatively, 
inhaled antigens can be carried by migratory DCs to the draining LNs where they are 
presented to antigen-specific T cells, a process that occurs over hours (147, 149). Unlike 
most antigens, we demonstrate in this report that inhaled SEA enters the blood circulation 
within minutes and can be recovered in the serum rather than associated with cells (Fig. 3-
1). This ability to enter the bloodstream while maintaining its full bioactivity accounts for the 
rapid systemic response observed after S. aureus enterotoxin pulmonary exposure (30, 39).  
From a biomedical perspective, our study showed that just as seen in many patients 
with SIRS/sepsis (150), SEA inhalation induced leukocytosis since the pulmonary SEA 
challenge initiated rapid recruitment of innate immune cells to blood followed by their 
migration to lymphoid tissues (Fig. 3-3). During inflammation, innate immune cells are often 
assumed to originate from BM. While the pool of inflammatory monocytes in the BM was 
markedly depleted, there was only a small decrease in BM neutrophils after SEA inhalation 
(Fig. 3-3, C). A second neutrophil reservoir is the marginated pool where the egress of 
neutrophils is much faster than the BM peaking at 2 h after an injection of a stimulant (151). 
The large increase in circulating neutrophils 2 h after SEA inhalation suggests that many of 
the recruited neutrophils originated from the marginated pool rather than BM.  
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Activation and expansion of T cells has been considered the core of S. aureus 
enterotoxin-induced inflammation (10). Nevertheless, several studies reported that an 
inflammatory response could occur even in the absence of T cells (152, 153). In the inhaled 
SEA model of SIRS, TCR βδ−/− mice were unable to recruit monocytes and neutrophils to 
blood and LNs whereas only a small transfer of T cells induced a rapid mobilization of the 
innate cells (Fig. 3-4). The recruited cells localized to the T cell zone of the LNs (Fig. 3-5). 
This specific location in the LNs renders an opportunity to modulate adaptive immunity. 
Previous studies showed that after recruitment to LNs, inflammatory monocytes differentiate 
into DCs and are capable of antigen presentation, including cross-presentation, resulting in 
enhanced Th1 responses via IL-12 (126, 127). Similarly, neutrophil migration to LNs has 
been associated with several different functions, including carrying bacteria to LNs via the 
lymphatic system, augmenting lymphocyte proliferation, and downregulating CD4 T cell 
responses by decreasing antigen presentation by antigen-presenting cells (122, 124, 154). 
Thus, it will be important to determine if the migration of inflammatory monocytes and 
neutrophils to the T cell zone of LNs affects the function of T cells and the overall 
inflammatory response after pulmonary S. aureus enterotoxin challenge.  
To test whether the recruitment of innate immune cells was caused by mediators 
directly released by T cells, we examined T cells for chemokine expression and found that 
upon activation, T cells expressed chemokines but also induced chemokine expression in 
DCs (Fig. 3-7). This was coincident with increases in inducible costimulatory pathways 
rapidly after SEA inhalation that included Tnfsf9 (4-1BBL) and Cd40lg (CD40L) (Fig. 3-9, E 
and F). However, while inducible costimulation was not involved in the monocyte and 
neutrophil chemotaxis (Fig. 3-10), blocking non-inducible CD28 costimulation significantly 
reduced the migration of inflammatory monocytes (Fig. 3-11). In contrast, neutrophil 
recruitment was driven by two T cell-dependent signals. Firstly, TNF triggered a rapid 
release of neutrophils into blood, which we postulate is derived from the marginated pool. 
Secondly, a chemokine axis induced by both the CD28 and TNF pathways directed 
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neutrophils to LNs (Fig. 3-11, E). In particular, the inhibition of neutrophil migration to LNs 
was coincident with reduced expression of Cxcl2 (Fig. 3-11, C and D) and it was previously 
reported that the migration of neutrophils into tumor-draining LNs via high endothelial 
venules was dependent on CXCL2 but not on CXCL1 (125). Therefore, we hypothesize that 
CXCL2 may be the key chemokine driving the neutrophil migration into LNs from blood after 
pulmonary challenge with S. aureus enterotoxins or during Gram-positive sepsis. Finally, we 
showed that T cells were essential for the systemic recruitment of neutrophils and 
monocytes after SEA inhalation (Fig. 3-4). However, because TNF can be produced by 
many cell types (155) and CD28 expression was reported on immune cells other than T 
cells (156, 157), it is possible that blocking with CTLA4-Ig and anti-TNF affected other cell 
populations that could also contribute to the reduced migration of innate cells. 
Despite decades of research, there is currently no approved drug treatment for 
SIRS/sepsis patients (7). Because of the central role TNF plays in the pathology of 
SIRS/sepsis, anti-TNF therapies were previously thought to be an excellent therapeutic 
target (158). However, clinical studies failed to find improvements in the outcomes of 
patients with sepsis receiving anti-TNF treatment (159-161). Moreover, rheumatoid arthritis 
patients on anti-TNF therapy gained a higher likelihood of developing serious infections 
(162). Our results show that although TNF blockade attenuated inflammation by reducing 
serum IL-6 (Fig. 3-11, B), it also significantly depleted the pool of circulating blood 
neutrophils (Fig. 3-11, E). The capacity of neutrophils to mount a rapid microbicidal 
response makes them a crucial component of the immune system during sepsis. In fact, the 
relative resistance to S. aureus in C57BL/6 mice was recently attributed to increased 
chemokine secretion and subsequent neutrophil recruitment compared to other mouse 
strains (163). In addition, reduced levels of circulating neutrophils may be associated with a 
decreased likelihood of survival in sepsis (142, 164). The suppressed neutrophil levels in 
blood could potentially compromise the immune system’s capacity to kill off bacteria in the 
bloodstream. Therefore, it is possible that the failure of anti-TNF therapies to ameliorate 
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outcomes in sepsis is partially due to the reduced neutrophil count in blood leading to 
increased bacteremia.  
Costimulatory molecules represent another group of potential therapeutic targets in 
SIRS/sepsis. In particular, CD28 may play an important role in the propagation of 
inflammation during the course of the disease. A clinical trial using a monoclonal 
superagonist anti-CD28 resulted in a life-threatening SIRS with clinical signs and symptoms 
similar to sepsis (165). In contrast, blocking CD28 signaling, especially in cases of 
superantigen-induced toxic shock, showed attenuation of the disease in mice (166, 167). 
Here we showed that blocking CD28 reduced IL-6 levels and chemokine expression, while 
impeding migration of monocytes and neutrophils to LNs without affecting neutrophilia in 
blood (Fig. 3-11). Therefore, targeting CD28, especially in cases of Gram-positive sepsis in 
which S. aureus enterotoxins may drive the pathology, merits further investigation.  
Lastly, not only costimulatory but also coinhibitory molecules, particularly Cd274 
(PD-L1), Pdcd1lg2 (PD-L2) and Pdcd1 (PD1), were upregulated after SEA inhalation (Fig. 3-
9). Similarly, both pro- and anti-inflammatory cytokines were upregulated as were the 
processes of cell activation and apoptosis (Fig. 3-9). In patients with sepsis, the acute SIRS 
phase characterized by a hyperinflammatory state and the release of pro-inflammatory 
cytokines was thought to be frequently followed by an immunosuppressive CARS phase and 
presence of anti-inflammatory cytokines (168). However, recent evidence suggests that both 
pro- and anti-inflammatory responses occur simultaneously from the onset of sepsis with 
one prevailing over the other during the course of the disease (7, 169, 170). Similarly, we 
showed that both inflammatory and immunosuppressive processes are triggered 
simultaneously in T cells immediately after SEA inhalation, confirming the relevance of S. 
aureus enterotoxins in the pathology of sepsis.  
In sum, our study demonstrated that inhaled SEA rapidly enters the bloodstream and 
triggers systemic inflammation by forming an inflammatory cell network comprised of both 
the innate and adaptive immune system. In particular, our findings revealed a dual 
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mechanism of monocyte and neutrophil recruitment by SEA-specific T cells relying on 
overlapping and non-overlapping roles of the non-inducible costimulatory receptor CD28 
and the inflammatory cytokine TNF. Treatments for SIRS/sepsis may benefit by targeting 
disease initiation rather than treating the consequent symptoms.  
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FIGURE 3-1: After inhalation, SEA circulates systemically via blood. Tail blood was 
collected 10 or 30 min after SEA or vehicle inhalation and the serum or blood cells were 
incubated overnight with enriched naïve T cells.  The expression of activation markers CD69 
and CD25 was measured on SEA-activated CD3+Vβ3+ T cells and on bystander CD3+Vβ14+ 
 	 42	
T cells by flow cytometry.  A) Representative histograms of CD69+ and CD25+ cells in 
CD3+Vβ3+ and CD3+Vβ14+ populations after a co-culture of naïve T cells with serum from 
SEA or vehicle mice. B) Percent of CD69+ and CD25+ cells in CD3+Vβ3+ and CD3+Vβ14+ 
populations after a co-culture of naïve T cells with serum from SEA or vehicle mice. C) 
Concentration of IL-2 in the supernatants from a co-culture between naïve T cells and serum 
or cells from blood harvested from SEA or vehicle mice. Data were combined from 3 
independent experiments with n=3 in vehicle group and n=6 in SEA group. Data are shown 
as mean ± SEM. Statistical significance was determined by two-tailed Student’s t-tests 
(*P<0.05; **P<0.01; ***P<0.001). 
 
 
Figure 3-2: Estimation of SEA levels in serum immediately after inhalation. Naïve 
enriched T cells were incubated overnight with increasing concentrations of SEA. The 
percentages of CD69+ and CD25+ cells in CD3+Vβ3+ and CD3+Vβ14+ was detected by flow 
cytometry. The dashed horizontal line represents the average percent of CD69+ or CD25+ 
cells in CD3+Vβ3+ T cells after a co-culture with serum (1:4 diluted in culture medium) from 
mice 10 min after SEA inhalation (see Fig. 3-1). Data were combined from 3 independent 
experiments with n=3. 
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FIGURE 3-3: SEA inhalation induces systemic migration of inflammatory monocytes 
and neutrophils. Peripheral blood, BM, LNs and spleen were collected after SEA or vehicle 
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inhalation. A) Representative plots of cervical LN cells 4 h after SEA or vehicle challenge to 
identify Lin−(CD3/CD19−)CD11b+Ly6G-Ly6Chi inflammatory monocytes and 
Lin−CD11b+Ly6G+Ly6C+ neutrophils. The percent is relative to live cell gate. B) Percent of 
monocytes and neutrophils in peripheral blood 2 and 4 h after SEA or vehicle challenge. 
Data were combined from 3 independent experiments with n=8 per group. C) Percent of 
inflammatory monocytes and neutrophils in LNs and spleen 4 and 12 h after SEA or vehicle 
challenge. Non-draining LNs = axillary, brachial, inguinal, and mesenteric LNs. Data were 
combined from 3 independent experiments with n=3 for vehicle group and n=6 for SEA 
group. D) Absolute number of inflammatory monocytes and neutrophils in BM from one 
femur and tibia 1.5 and 4 h after SEA or vehicle challenge. Data were combined from at 
least 3 independent experiments with n=6-8 per group. Data are shown as mean ± SEM. 
Statistical significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01; 
***P<0.001). 
 
 
FIGURE 3-4: T cells are required for the systemic recruitment of inflammatory 
monocytes and neutrophils after SEA inhalation. TCR βδ−/− mice received C57BL/6J T 
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cells or nothing. On the next day, they were challenged with SEA or vehicle and cervical 
LNs and peripheral blood were collected 6 h after the challenge to identify 
Lin−(CD3/CD19−)CD11b+Ly6G-Ly6Chi inflammatory monocytes and Lin−CD11b+Ly6G+Ly6C+ 
neutrophils. For cervical LNs, data were combined from at least 4 independent experiments 
with n = 8-12 per group. For peripheral blood, data were combined from at least 3 
independent experiments with n = 6-10 per group. Data are shown as mean ± SEM. 
Statistical significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01; 
***P<0.001). 
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FIGURE 3-5: Inflammatory innate immune cells migrate to the T cell zone of the LNs 
after SEA inhalation. A) Representative confocal microscopy images of frozen sections 
from cervical LNs 1, 2 and 4 h after SEA or vehicle challenge. Inflammatory innate immune 
cells (monocytes and neutrophils) were labeled with anti-CD11b and anti-7/4 antibodies. 
The white dashed line marks B cell follicles and was determined by anti-B220 staining (not 
shown). The vertical panel on the right represents an enlarged image of the area in the 
white square. The displayed images are projections of confocal z stacks taken using 20× 
 	 47	
magnification/0.8 numerical aperture objective and Zeiss LSM780 confocal microscope. 
Scale bar = 80 µm. B) Number of 7/4+ cells. The amount of 7/4+ cells per field was 
determined from 3 images per mouse by Imaris (Bitplane). Statistical significance was 
assessed by two-tailed Student’s t-tests (***P<0.001). C) Position of 7/4+ cells in LNs. The 
number of 7/4+ cells in B cell follicles vs. T cell zone was determined from 3 images per 
mouse by Imaris. The data are representative of least 3 independent experiments with n=3-
5 per group. 
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FIGURE 3-6: SEA inhalation causes an increased expression of monocyte and 
neutrophil chemotactic factors in LNs. A) Changes in chemokine gene expressions after 
SEA inhalation. Draining LNs (cervical and mediastinal) were collected 1, 2 or 4 h after SEA 
or vehicle inhalation and lysed to isolate RNA. qRT-PCR expression was normalized to β-
actin and is represented as a fold change relative to vehicle-treated group (dashed line set 
as 1). Individual chemokine expressions were divided into 3 groups based on their 
 	 49	
expression patterns (early increase in expression:  ; late increase in expression: n; late 
decrease in expression: n). Data were combined from 3 independent experiments with n = 7 
per group. Data are shown as mean + SEM. B) Changes in chemokine protein levels after 
SEA inhalation. Draining LNs were collected 4 or 16 h after SEA or vehicle exposure. Whole 
tissue was lysed with magnetic beads and chemokine expressions were measured with a 
multiplex assay. Data were combined from three independent experiments with n = 6 (4 h 
exposure) or n = 3 (16 h exposure). Data are shown as mean ± SEM. Statistical significance 
was determined by two-tailed Student’s t-tests (*p<0.05; **p<0.01; ***p<0.001). 
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FIGURE 3-7: T cells and DCs express chemokines after SEA inhalation. LNs (axillary, 
brachial, inguinal, mesenteric, cervical and mediastinal) were collected 2 h after SEA or 
vehicle challenge and cells were stained to sort for specific populations. RNA isolated from 
the sorted populations was used for qRT-PCR analysis. A) Expression of Cxcl1, Cxcl2, Ccl3 
and Ccl4 in CD3−CD19−(or B220−)NK1.1−DX5−MHC II+CD11c+ conventional DCs (cDCs). B) 
Expression of Ccl3 and Ccl4 in Vβ3+ and Vβ14+ T cells. C) Gating strategy to isolate 
migratory and resident DCs. D) Expression of Cxcl1 and Cxcl2 in migratory and resident 
DCs. Expression of chemokines is shown relative to β-actin. Data are displayed as mean + 
SEM. Data are representative of 3 independent experiments with n=3 per group. Statistical 
significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01; ***P<0.001). 
 
 
FIGURE 3-8: Migratory DCs present SEA to T cells. A) Gating strategy used to sort for 
DC subpopulations. B) CD69 expression on T cells after co-culture with ex vivo derived 
DCs. LNs were harvested 40 min after SEA or vehicle inhalation and the sorted DC 
subpopulations were co-cultured with naïve T cells. The expression of CD69 was measured 
on SEA-activated CD3+Vβ3+ T cells and on bystander CD3+Vβ14+ T cells by flow cytometry. 
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Data are displayed as mean ± SEM and are representative of 4 independent experiments 
with n=4 per group. Statistical significance was determined by two-tailed Student’s t-tests 
(*P<0.05; **P<0.01; ***P<0.001).  
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FIGURE 3-9: SEA simultaneously activates and suppresses T cells. LNs were removed 
40 min after SEA or vehicle inhalation. The total RNA from the sorted Vβ3+ and Vβ14+ T 
cells was used for genomic sequencing. A) Purity of Vβ3+ cells and Vβ14+ cells. The percent 
is relative to live cell gate. B) Heat map of the most downregulated and upregulated genes 
in SEA-activated Vβ3+ T cells compared to vehicle Vβ3+ T cells and SEA Vβ14+ T cells 
(control groups). Genes that had a significantly altered expression (log2 fold change ≤ −1.5 
or ≥ +1.5) in SEA-activated Vβ3+ cells compared to either vehicle Vβ3+ T cells or SEA Vβ14+ 
T cells in all 3 experiments were selected. C) Net enrichment score (NES) for gene ontology 
clusters upregulated in SEA-activated Vβ3+ cells compared to control groups (GSEA; 
*P<0.01). D) Log2 fold change in the expression of cytokines in SEA-activated Vβ3+ T cells 
compared to vehicle Vβ3+ T cells. Significant difference is represented by a dashed line 
(≥1.5). Data are shown as mean ± SEM. E) Heat map showing expression of inducible and 
constitutively expressed costimulatory molecules in SEA Vβ3+ T cells and control groups 
(vehicle Vβ3+ and SEA Vβ14+ T cells) 40 min after SEA or vehicle inhalation. F) Log2 fold 
change in the expression of costimulatory molecules in SEA-activated Vβ3+ T cells 
compared to vehicle Vβ3+ T cells. Significant difference is represented by a dashed line 
(≥1.5). Data are displayed as mean ± SEM. G) Heat map of coinhibitory molecules in SEA-
activated Vβ3+ T cells and vehicle Vβ3+ and SEA Vβ14+ control groups. H) Log2 fold change 
in the expression of coinhibitory molecules in SEA Vβ3+ T cells compared to vehicle Vβ3+ T 
cells. Significant difference is represented by a dashed line (≥1.5). Data are displayed as 
mean ± SEM. Data are representative of 3 independent experiments with n=3 per group.  
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FIGURE 3-10: Inducible costimulatory molecules 41BBL and CD40L are not involved 
in the recruitment of monocytes and neutrophils after SEA inhalation. A) and B) 
Percent of Lin−(CD3/CD19/NK1.1−)CD11b+Ly6G-Ly6Chi monocytes (A) and 
Lin−CD11b+Ly6G+Ly6C+ neutrophils (B) in draining LNs (cervical and mediastinal) and blood 
in mice treated with anti-4-1BBL or anti-CD40L prior to SEA challenge. Two hours prior to 
SEA inhalation, mice were treated with anti-4-1BBL or anti-CD40L or the respective IgG 
control i.p. Blood and draining LNs were removed 4 hours after the SEA challenge. Data 
were combined from 2 independent experiments with n=6 per group. Data are shown as 
mean ± SEM. Statistical significance was determined by two-tailed Student’s t-tests. 
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FIGURE 3-11: The migration of monocytes and neutrophils after SEA inhalation is 
dependent on CD28 and TNF. A) The NFκB signaling via TNF is upregulated in SEA-
activated Vβ3+ T cells 40 min after SEA inhalation. GSEA was used to evaluate significantly 
enriched pathways in SEA-activated Vβ3+ cells compared to the control groups (vehicle 
Vβ3+ cells and SEA Vβ14+ cells). Data are representative of 3 independent experiments with 
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n=3 per group. B) Concentration of serum IL-6 in mice treated with CTLA4-Ig or anti-TNF 
prior to i.n. SEA challenge. Two hours prior to SEA inhalation, mice were treated with 
CTLA4-Ig or anti-TNF antibody or the respective IgG control i.p. Serum was collected 4 
hours after SEA challenge. C) Chemokine expressions in non-draining LNs (mesenteric, 
axillary, brachial, inguinal) from mice that were treated with either CTLA4-Ig or anti-TNF and 
the respective IgG control prior pulmonary SEA challenge. Tissue was collected 4 hours 
after the SEA challenge. The qRT-PCR expression was normalized to β-actin and it is 
expressed as a fold change relative to the IgG-treated group. D) and E) Percent of 
Lin−(CD3/CD19/NK1.1−)CD11b+Ly6G-Ly6Chi monocytes (D) and Lin−CD11b+Ly6G+Ly6C+ 
neutrophils (E) in draining LNs (cervical and mediastinal) and blood in mice treated with 
CTLA4-Ig or anti-TNF prior to SEA inhalation. Tail blood and draining LNs were collected 4 
h after SEA challenge. Data were combined from 3 independent experiments with n=7-9 per 
group. Data are shown as mean ± SEM. Statistical significance was determined by two-
tailed Student’s t-tests (*P<0.05; **P<0.01; ***P<0.001). F) and G) Correlating the percent of 
D-LNs (draining LNs) neutrophils with the percent of neutrophils in blood (F) and ND-LNs 
(non-draining LNs) Cxcl2 expression (G). Data are representative of 3 independent 
experiments with n=9 per group. The P value of the linear regression fit curve is calculated 
from F test. 
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TABLE 3-1: SEA inhalation rapidly alters expression of multiple genes in Vβ3+ T cells. 
Mice were challenged with SEA or vehicle and LNs were removed 40 min after the 
challenge. The cells were sorted for Vβ3+ and Vβ14+ cells and the total RNA from the sorted 
cells was used for transcriptome sequencing analysis. Expression of genes from SEA-
activated Vβ3+ T cells was compared to the expression in vehicle Vβ3+ and SEA Vβ14+ 
control groups. Genes that had a significantly decreased (log2 fold change ≤ −1.5) or 
increased (log2 fold change ≥ +1.5) expression in SEA-activated Vβ3+ T cells compared to 
either vehicle Vβ3+ or SEA Vβ14+ T cells in all 3 experiments were selected. The table lists 
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genes (symbols and names) with decreased (blue) or increased (red) expression in SEA-
activated Vβ3+ cells compared to the controls. Data are representative of 3 independent 
experiments with n=3 per group.  
 
TABLE 3-2: Genes enhanced by CD28 signaling are upregulated by T cells after SEA 
inhalation. The table shows genes with increased expression in SEA Vβ3+ T cells 
compared to the vehicle Vβ3+ control group that were previously shown to be enhanced by 
CD28 signaling (138-140). The log2 fold change is an average of log2 fold changes in SEA-
activated Vβ3+ T cells vs. vehicle Vβ3+ T cells from 3 independent experiments. For some of 
the genes, log2 fold change could not be calculated as the expression of these genes was 
not detected in one or more of the samples in the vehicle Vβ3+ group (labeled N/A). Data 
are representative of 3 independent experiments with n=3 per group.  
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Chapter 4: Pulmonary Response Following S. aureus Enterotoxin A Inhalation  
 
This work was published in the American Journal of Physiology – Lung Cellular and 
Molecular Physiology, vol. 313, issue 1, pp. 177-191, July 1, 2017 under the title 
“Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced 
acute lung injury” and was authored by: Julia Svedova, Antoine Ménoret, Payal Mittal, 
Joseph M. Ryan, James A. Buturla, and Anthony T. Vella. 
 
 
Abstract 
 
Acute respiratory distress syndrome (ARDS) is a serious, often fatal condition without 
available pharmacotherapy. While the role of innate cells in ARDS has been studied 
extensively, emerging evidence suggests that T cells may be involved in disease etiology. 
Staphylococcus aureus enterotoxins are potent T cell mitogens capable of triggering life-
threatening shock. We demonstrate that 2 days after inhalation of S. aureus enterotoxin A, 
mice developed T cell-mediated increases in vascular permeability, as well as expression of 
injury markers and caspases in the lung. Pulmonary endothelial cells underwent sequential 
phenotypic changes marked by rapid activation coinciding with inflammatory events 
secondary to T cell priming, followed by reductions in endothelial cell number juxtaposing 
simultaneous T cell expansion and cytotoxic differentiation. Although initial T cell activation 
influenced the extent of lung injury, CD54 (ICAM-1) blocking antibody administered well 
beyond enterotoxin exposure substantially attenuated pulmonary barrier damage. Thus, 
CD54-targeted therapy may be a promising candidate for further exploration into its potential 
utility in treating ARDS patients. 
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Introduction 
 
  Despite decades of research, acute lung injury (ALI)/acute respiratory distress 
syndrome (ARDS) remains an underdiagnosed and undertreated life-threatening condition 
and accounts for over 10% of all intensive care unit admissions (87). ALI/ARDS is a 
syndrome of acute lung inflammation that presents with bilateral lung infiltrates, pulmonary 
edema, and hypoxemia (88).  The mechanism of ALI/ARDS involves a pulmonary or 
extrapulmonary insult such as pneumonia, aspiration, sepsis or major surgery, leading to a 
recruitment of leukocytes and platelets, release of pro-inflammatory factors, and injury to the 
endothelial and epithelial layers. Disruption of the pulmonary endothelial barrier ultimately 
precipitates the characteristic pathophysiological changes of increased vascular 
permeability, accumulation of protein-rich fluid, and impaired gas exchange (88, 171).  
The two most frequent underlying causes are pneumonia and sepsis, with most 
patients developing ALI/ARDS secondary to an established bacterial, viral or fungal infection 
(88). Both Gram-positive and Gram-negative bacteria can be involved (172, 173), but 
previous studies have preferentially focused on Gram-negative bacteria and, more 
specifically, the effects of their bacterial-derived LPS (174). Importantly, however, there are 
many cases of ALI/ARDS that are likely associated with Gram-positive bacteria, and 
Staphylococcus aureus in particular, which is a major contributor to morbidity and mortality 
resulting from serious infections (12, 175). One of the critical virulence factors of S. aureus 
capable of inducing massive inflammation are enterotoxins (10, 176). These superantigens 
bypass classical antigen presentation processes and instead induce oligoclonal expansion 
of T cells by bridging MHC II with a specific T cell receptor Vβ chain (10). Superantigens are 
known for their extreme potency; unlike conventional antigens activating 1/104-106 T cells, 
superantigens can activate up to 1/4 T cells (22). The resultant T cell-induced inflammatory 
response and cytokine storm (most notably, IL-2, IFNγ and TNF) can have disastrous 
consequences leading to toxic shock, tissue damage, organ dysfunction and even death (9, 
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10). Most S. aureus strains produce superantigen toxins and recent evidence suggests that 
they may be involved in a number of serious illnesses, including pneumonia, sepsis, and 
endocarditis (9, 16). S. aureus enterotoxin A (SEA) has been found in patients with sepsis, 
and its prevalence correlated with infection severity (79, 80). In animal studies, organ 
damage and lethality caused by S. aureus induced bacteremia or necrotizing pneumonia 
were shown to be superantigen-dependent (85, 96, 177). Furthermore, it was demonstrated 
that CD4+ T cell activation significantly exacerbated murine lung pathology and impaired 
bacterial clearance in pneumonia caused by an enterotoxin-producing S. aureus strain 
(178). Thus, S. aureus enterotoxins likely play a crucial role in the severity of sepsis, 
pneumonia, and the associated ALI/ARDS.  
Previous studies showed that administration of S. aureus enterotoxin in animal 
models resulted in acute pulmonary inflammation (34, 179-181) and this response appeared 
to be mediated by T cells (30, 39, 182). In particular, inhalation of S. aureus enterotoxin 
firstly induced a systemic inflammatory response characterized by rapid T cell activation, 
cytokine and chemokine release, and a T cell-orchestrated recruitment of innate immune 
cells into the circulation, lymphoid tissues and lung (30, 34, 183, 184). This early response 
occurring within several hours of S. aureus enterotoxin exposure was followed by 
development of considerable lung pathology at 48 h after inhalation, which was marked by a 
massive T cell expansion in lymphoid tissues and lung (34, 39). Importantly, no lung 
pathology was found in the absence of T cells, in particular CD8+ T cells (39). The 
pulmonary response presented with perivascular and peribronchial inflammation, disruption 
of terminal vessels and accumulation of proteins, red blood cells and leukocytes in the 
airways (34, 39, 105, 106). These pathological features strongly resemble the histological 
findings in ALI/ARDS patients (88, 171), suggesting that S. aureus enterotoxin-activated T 
cells may be capable of inducing ALI/ARDS. Although T cells were previously found to 
orchestrate both the early inflammatory responses and the subsequent lung inflammation 
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(30, 39, 183), the mechanism driving the development of vascular permeability is not fully 
understood.  
The goal of the this work was to define how SEA inhalation alters the pulmonary 
barrier over time and to establish the main molecular players involved in the development of 
lung injury, in order to identify clinically translatable therapeutic targets. We show that S. 
aureus enterotoxin inhalation caused increased vascular permeability, elevated expression 
of endothelial and epithelial injury markers, increased caspase expression in lung, and a 
temporal differential cytokine/chemokine profile distinguishing intrapulmonary and systemic 
responses. Mechanistically, S. aureus enterotoxin triggered rapid activation of pulmonary 
endothelial cells in the early phase of inflammation, which was followed by significant 
reductions in endothelial cell number during the late phase of inflammation, marked by 
massive T cell expansion and cytotoxic differentiation. The early inflammatory responses 
due to S. aureus enterotoxin-induced T cell activation in part determined the extent of 
pulmonary barrier damage. However, remarkably, lung injury could be mitigated by 
therapeutic blockade of CD54, also known as intercellular adhesion molecule-1 (ICAM-1), 
when administered 36 h after initiation of inflammation. Thus, our data show that ALI/ARDS 
may be treatable with immunotherapeutic agents given hours, or perhaps even days, 
beyond the onset of inflammatory response. 
 
Results 
 
S. aureus Enterotoxin Inhalation Induces Lung Injury Marked By Cell Death 
 We have previously shown that upon local inhalation, SEA was detectable in serum 
within minutes and triggered systemic activation of T cells. This systemic inflammatory 
response was marked by cytokine and chemokine release, as well as innate cell migration 
into the circulation and lymphatic tissue (183). Furthermore, activation of SEA-specific αβ T 
cells induced IL-17 release by γδ T cells, which further aided recruitment of neutrophils into 
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lung (30). Despite these rapid inflammatory responses occurring within the first 8 h, lung 
alveolitis manifested only 2 days after SEA inhalation (39). These data suggested that in the 
time period between the first minutes of systemic T cell activation and the appearance of 
extensive lung histopathology at 48 h, a communication web was formed between the 
systemic response and the lung mucosa, ultimately resulting in deterioration of the 
pulmonary barrier function.  
In line with this hypothesis, we tested for increased lung permeability and the 
appearance of cellular injury markers and cell death following SEA inhalation. Lung 
permeability was assessed by administering FITC-dextran, i.n. or i.v., and then measuring 
fluorescence in the serum (lung-to-blood) or in the BAL fluid (blood-to-lung), respectively. 
While there was no difference in permeability at 24 h in the SEA-treated mice compared to 
vehicle, permeability was significantly increased by 48 h after SEA (Fig. 4-1, A). Importantly, 
albumin was also increased in BAL fluid at 48 h (Fig. 4-1, B).  
 It was previously shown that after S. aureus enterotoxin inhalation acute alveolitis 
correlated with increased T cell and innate immune cell presence in the BAL fluid and lung 
(30, 34, 39, 105, 180).  Here, it is shown that 48 h after SEA inhalation, clusters of SEA-
specific Vβ3+ T cells were concentrated at the interstitial areas surrounding bronchioles and 
perivascular regions (Fig. 4-1, C). Additionally, these specific Vβ3+ T cells co-localized with 
CD11b+7/4+ inflammatory innate cells, and this area of inflammation was further 
characterized by the presence of enlarged CD169+ lung macrophages (Fig. 4-1, C). The 
dramatic changes in the inflammatory cell number and lung permeability suggested that 
SEA inhalation could induce injury to pulmonary epithelial and endothelial cells. Indeed, 
CD54, RAGE, and angiopoietin-2, which are established markers of epithelial and 
endothelial cell injury in ALI/ARDS (185), were significantly increased in BAL fluid 48 h after 
SEA inhalation but not at 24 h post-SEA (Fig. 4-1, D).  
In a previous report, it was shown that mice lacking T cells (TCR βδ−/− mice) did not 
develop any lung pathology following SEA inhalation. Furthermore, CD4-depleted WT mice 
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showed a partial abrogation of the inflammatory response whereas CD8-depleted mice had 
an almost complete abrogation of pulmonary inflammation (39). These findings suggested 
that the inflammatory response to SEA could not occur in the absence of T cells. 
Nevertheless, T cell-independent responses to a S. aureus enterotoxin have been reported 
(153). Therefore, to further establish the role of T cells in SEA-induced pulmonary injury, WT 
and TCR βδ−/− mice were exposed to SEA or vehicle and BAL fluid was collected 48 h after 
inhalation. Unlike WT mice, SEA-exposed TCR βδ−/− mice did no show any differences in 
the total number of BAL fluid cells, albumin concentration as well as the endothelial injury 
marker angiopoietin-2 (186), when compared to the vehicle control (Fig. 4-2, A), confirming 
the critical role of T cells in inducing lung injury after SEA inhalation. 
 It was next hypothesized that the increased number of inflammatory cells and the 
presence of injury markers in BAL fluid were associated with apoptosis, particularly 
occurring in tissues with significant T cell expansion, i.e. lung and spleen (39). To test this, 
SEA- or vehicle-exposed mice received a pan-caspase-binding fluorescent probe prior to 
sacrifice and the relative fluorescence levels in lung and spleen were measured. Both lung 
and spleen from SEA-treated mice showed significantly greater fluorescence than control, 
indicating an increase in cell death in tissues with expanded T cell population (Figs. 4-2, B 
and C). To confirm that T cells were mediating the observed increase in caspase expression 
in the lung and spleen, the study was repeated using TCR βδ−/− mice. No differences in 
relative fluorescence between the tissues were found, demonstrating that T cells are 
required for the induction of caspases in the lung (Figs. 4-2, B and C). To further validate 
these findings, lung tissue sections were examined for the presence of active caspase-3, an 
irreversible marker of cell death (187). Lungs from SEA-treated mice had a greater number 
of active caspase-3+ cells relative to vehicle control (Fig. 4-2, D and E). Thus, SEA 
inhalation caused clustering of inflammatory cells to the interstitial bronchioles and 
perivascular regions, expression of epithelial and endothelial injury markers, and an 
increase in cell death, ultimately giving rise to increased pulmonary permeability. 
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S. aureus Enterotoxin Triggers Early And Delayed Inflammation Which Activates and 
Subsequently Reduces the Number of Lung Endothelial Cells 
 Previous studies showed that development of pulmonary inflammation at 48 h was 
preceded by a rapid systemic inflammatory response in the first several hours after S. 
aureus enterotoxin inhalation. This response involved activation of enterotoxin-specific T 
cells, robust cytokine and chemokine release, and a recruitment of innate immune cells into 
circulation, lymphoid tissues, and lung (30, 34, 183). Our findings in Fig. 4-1, however, 
suggested that there was no pulmonary injury or change in lung permeability at 24 h.  In 
order to better understand the relationship between the early inflammatory events and 
development of lung injury at 48 h, we performed a multiplex assay on mouse serum and 
BAL fluid obtained 4, 14, 24 or 48 h after SEA inhalation. As predicted, SEA induced 
massive increases in serum cytokines and chemokines 4 h after inhalation (Fig. 4-3). These 
levels dropped off by 14 h and were not different from the vehicle control by 24 h. In sharp 
contrast, the proinflammatory cytokines/chemokines in BAL fluid were increased only at 48 
h, with the exceptions of CXCL1 and IL-12p40 (Fig. 4-3). The early presence of CXCL1 and 
IL-12p40 in BAL fluid could not be due to leakage from systemic circulation because, like 
CXCL1 and IL12-p40, IL-6, G-CSF and CCL2 were markedly elevated in blood at 4 h, but 
were not found in BAL fluid at the early time points. Therefore, we concluded that CXCL1 
and IL-12p40 were likely produced locally rather than permeated from blood to BAL fluid. 
This finding was consistent with our previous report showing that IL-17 release by 
pulmonary γδ T cells promotes recruitment of neutrophils to the lung by 8 h after SEA 
inhalation (30).  
 To further study pulmonary response diversity prior to the onset of injury, lung cells 
were obtained from mice 14 or 40 h after SEA or vehicle inhalation, barcoded, stained with 
heavy metal-conjugated antibodies and analyzed by cytometry by time-of-flight (CyTOF), 
also known as mass cytometry. The high-dimensional cytometry data were visualized as 
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colorimetric 2-dimensional ViSNE maps (188), which cluster single-cell data based on 
similarity in marker expression patterns. Furthermore, because the individual samples were 
barcoded, pooled, and acquired simultaneously by CyTOF, each map represents all four 
samples (14 h vehicle, 14 h SEA, 40 h vehicle, 40 h SEA). Using combinations of lineage 
markers, we identified various lung cell populations to discern which cells were stimulated 
after SEA inhalation (Fig. 4-4). We first looked at SEA-specific Vβ3+ T cells; however, 
insufficient numbers of specific T cells could be collected at 14 h, likely due to activation-
induced increased adherence to the tissue (189). Nevertheless, CD8+Vβ3+ and CD4+Vβ3+ T 
cells (Fig. 4-5, A) isolated 40 h after SEA inhalation showed upregulation of pSTAT5 and 
DNA content (Fig. 4-5, B), consistent with activation and proliferation. Interestingly, even 
non-responding bystander CD4+Vβ14+ T cells showed some increase in STAT 
phosphorylation (Figs. 4-5, A and B) but not to the extent of SEA-specific T cells. These 
findings confirmed that CyTOF could be used to identify changes in cell signaling. 
CD11c+MHC II+ dendritic cells (Fig. 4-5, C) were slightly activated at 14 h but more robustly 
at 40 h as indicated by increased pSTAT3 (Fig. 4-5, D). Notably, CD45−CD31+CD54+ 
endothelial cells (Fig. 4-5, E) had upregulated pSTAT1 and MHC II and some 
downregulation of IκB as early as 14 h after SEA inhalation (Fig. 4-5, F). These results were 
replicated in 3 additional independent experiments (Fig. 4-5, G-I). Finally, STAT 
phosphorylation in other lung cell populations trended with their lineages (Fig. 4-5, J and K). 
Overall, these data suggest that endothelial cells became activated early but were able to 
maintain their function as there were no changes in pulmonary permeability or injury 
markers at 24 h (Fig. 4-1).  
 To study endothelial cell activation, lung cells were collected 14, 24 or 40 h after SEA 
or vehicle inhalation, sorted for CD45−CD31+CD54+ endothelial cells and then analyzed for 
gene expression. Sorted cells displayed a number of dynamic changes in response to SEA 
(Fig. 4-6, A). Expression of integrin Vcam1 were increased at 14 h (Fig. 4-6, A), likely 
signifying early activation. Interestingly, the expression of Nos3 (endothelial nitric oxide 
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synthase), an enzyme essential to endothelial cell homeostasis (190, 191) was firstly 
upregulated at 24 h and then downregulated at 40 h (Fig. 4-6, A). Finally, Icam1 (CD54) 
expression was increased two-fold over vehicle at 40 h post-SEA inhalation (Fig. 4-6, A). In 
addition to these sequential phenotype changes in pulmonary endothelial cells, there was a 
significant reduction in their numbers at 48 h after SEA (Fig. 4-6, B), and endothelial cell 
percentage inversely correlated with percentage of SEA-specific Vβ3+ T cells in the lung 
(Fig. 4-6, C). Endothelial cells from SEA-exposed mice also showed increased CD54 and 
CD95 (Fas) expressions (Fig. 4-6, D), and similarly, SEA-specific Vβ3+ T cells had greater 
expression levels of CD11a (receptor for CD54) and CD95 (Fig. 4-6, E). Granzyme B was 
also measured since it was found to increase in cases of septic ALI/ARDS patients (192). 
Indeed, SEA-specific Vβ3+ T cells were found to have upregulated granzyme B expression 
(Fig. 4-6, E), but, most importantly, robust levels of granzyme B were detected in BAL fluid 
at 48 h (Fig. 4-6, F). Thus, as lung permeability manifested at time points beyond 24 h (Fig. 
4-1, A), there were coincident increases in markers of cytotoxicity and cell death, particularly 
granzyme B and CD95.   
 
S. aureus Enterotoxin-Induced Lung Injury Is Dependent on T Cell Costimulation, But 
Therapy Is Possible Through CD54 Interference 
 It was previously demonstrated that systemic recruitment of neutrophils and 
monocytes after S. aureus enterotoxin-induced T cell activation was uniquely regulated by 
TNF and CD28 costimulation (183). Thus, it was hypothesized that preventing early 
inflammation with CD28 or TNF blockade would minimize the increase in pulmonary 
permeability. Mice were pre-treated with the CD28 signaling inhibitor CTLA4-Ig, anti-TNF 
antibody or IgG control 2 h prior to SEA inhalation and at 48 h post-SEA BAL fluid and lung 
were harvested (Fig. 4-7, A). CTLA4-Ig and anti-TNF pre-treatment significantly reduced 
BAL fluid cell numbers (Fig. 4-7, B), whereas CTLA4-Ig, but not anti-TNF, decreased the 
overall proportion of T cells and inflammatory innate cells in the BAL fluid (Fig. 4-7, C; 
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p=0.043 for CTLA4-Ig and p=0.12 for anti-TNF). Importantly, anti-TNF and CTLA4-Ig 
significantly reduced the presence of albumin and some of the injury and inflammation 
markers, but CTLA4-Ig was more potent overall at attenuating the lung injury (Fig. 4-7, D). 
Additionally, CTLA4-Ig decreased the total number of monocytes in lung (Fig. 4-7, E). Thus, 
early inflammatory responses define in part the severity of S. aureus enterotoxin-mediated 
lung injury.  
Despite the role played by early inflammatory responses in influencing the extent of 
lung injury, therapeutic strategies to block them have limited translational relevance when 
taking into consideration the typical disease progression and time scales involved, as well 
as the logistics of diagnosing and treating patients in the hospital. Alternatively, we 
investigated later events in the SEA-induced response, during which time entry and 
accumulation of lung T cells is evident. Pulmonary tissue and endothelial cells in particular, 
can be injured in a number of ways, including mechanisms involving cytokines and direct 
death pathways such as CD95 signaling (191, 193, 194). Additionally, CD54 was previously 
shown to enhance leukocyte transmigration and promote cytotoxic T cell function (195-197). 
Thus, CD95 and CD54 (Fig. 4-6, D) could be essential mediators of pulmonary barrier 
damage occurring later in the SEA response progression. 
We therefore hypothesized that CD95 and/or CD54 blockade would prevent 
pulmonary barrier leakiness at clinically relevant time points beyond the initiation of 
inflammation. Thus, 36 h after SEA inhalation mice were treated with anti-CD178 (ligand for 
CD95; FasL), anti-CD54 or IgG control, and BAL fluid and lung were collected at 48 h (Fig. 
4-8, A). While anti-CD178 showed no change in total cell number, anti-CD54 significantly 
reduced the total number of cells in BAL fluid (Fig. 4-8, B) and also decreased the overall 
proportion of T cells and inflammatory innate cells present (p=0.0012, Fig. 4-8, C). 
Importantly, anti-CD54 therapy potently decreased the measured injury markers (CD54 and 
RAGE), inflammatory markers (granzyme B, IFNγ and IL-6), and albumin in BAL fluid (Fig. 
4-8, D). Paradoxically, BAL fluid TNF levels were increased with anti-CD54 treatment (Fig. 
 	 71	
4-8, D). This overall reduction in inflammation was not limited to soluble factors, since CD54 
blockade also reduced the total numbers of SEA-specific Vβ3+ T cells lung (Fig. 4-8, E). 
Interestingly, anti-CD178 treatment only increased the number of neutrophils in the lung 
while having no effect on measures of lung injury (Fig. 4-8, D and E). To validate the effect 
of anti-CD54 on preserving lung barrier integrity, mice were treated with anti-CD54 or IgG 
control 36 h after SEA inhalation, and lung permeability was measured with FITC-dextran 
(as described previously) at 48 h. Indeed, the anti-CD54-treated mice showed significantly 
lower levels of FITC fluorescence in BAL fluid relative to IgG-treated mice, but not 
statistically different from vehicle control (p=0.27; Fig. 4-8, F). While CD54 blockade reduced 
total numbers of SEA-specific T cells in the lung by 45% (Fig. 4-8, E), we also observed 
substantial decreases in BAL fluid IFNγ and granzyme B levels (73% and 76%, respectively) 
in the treated mice (Fig. 4-8, D). These findings suggest that anti-CD54 therapy might 
directly diminish T cell cytotoxic potential, in addition to reducing pulmonary T cell infiltration. 
However, there was no difference in IFNγ and granzyme B expressions by SEA-specific 
CD8+ T cells (Fig. 4-8, G), suggesting that the synthesis of cytotoxic molecules was not 
markedly impacted by the therapy. In sum, these findings demonstrate that anti-CD54 
therapy significantly attenuates S. aureus enterotoxin-mediated lung injury well after the 
initiation of inflammation. 
 
Discussion 
 
 ALI/ARDS is a life-threatening condition that affects approximately 200,000 people in 
the United States annually, but despite recent advances in supportive care, the mortality 
rates remain unacceptably high (87, 88, 171). Although many clinical studies investigated 
various pharmacotherapies for ALI/ARDS, results have been mostly disappointing (8, 171). 
Thus, there is an urgent need to better understand the mechanisms of tissue injury in order 
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to design novel treatments for ALI/ARDS, and we propose CD54 as a promising 
immunotherapeutic target.  
While the role of innate cells, particularly neutrophils and macrophages, has been 
studied extensively in ALI/ARDS (129, 198), the involvement of adaptive immunity, T cells, 
in particular, is only now beginning to emerge (90). Prior studies showed that ALI/ARDS 
patients present with greater numbers of lymphocytes in circulation (91) and in BAL fluid 
(92). Furthermore, the T cell growth factor IL-2 was found to be elevated in BAL fluid of 
ARDS patients and was strongly associated with increased mortality (93, 94). ARDS 
alveolar T cells also showed significant increases in activation, proliferation, and cytokine 
secretion (199). In mouse models of ALI, Th17 cells were shown to be pathogenic (92), 
while Tregs were essential for recovery (200). Nevertheless, the mechanism of T cell-based 
pulmonary injury is unclear. Similar to LPS and bleomycin inhalation in mice (201), SEA 
models acute lung injury but with greater emphasis on the role of T cells. It is important to 
note that enterotoxins, including SEA, have been detected in the circulation of intensive care 
unit patients (79), and also in S. aureus isolates from individuals with complications from 
pneumonia (177, 202). This only suggests an association of S. aureus enterotoxins with 
ARDS, but non-human primates exposed to aerosolized enterotoxin exhibited severe 
pulmonary lesions with lethality in some subjects (98). Thus, there is a critical need to 
attempt to identify S. aureus enterotoxin protein in BAL fluid of ALI/ARDS patients. 
  To explore the mechanisms governing the development of ALI following S. aureus 
enterotoxin inhalation, we first defined the inflammatory changes that take place in the lung 
in terms of two distinct phases. The initial response is caused by rapid, oligoclonal T cell 
activation leading to robust cytokine and chemokine release (Fig. 4-3), and recruitment of 
neutrophils and monocytes into circulation followed by their appearance in the lung (30, 
183). This phase of the response occurs within hours after SEA inhalation. Here we found 
that the early inflammatory responses were accompanied by changes in cell signaling and 
the appearance of activation markers of endothelial cells. Upregulation of pSTAT1 and MHC 
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II (potentially in response to IFNγ stimulation (203, 204)) and changes in mRNA expression 
levels of integrin Vcam1 was evident (Figs. 4-5, F and 4-6, A). However, there were no 
changes in lung permeability or signs of damage noted (Fig. 4-1) and the barrier was also 
impermeable even to the high levels of circulating cytokines found in the serum at 4 h (Fig. 
4-3).  
 Lung permeability was clearly increased at 48 h (Fig. 4-1, A), which coincides with 
the second phase of the inflammatory response marked by robust T cell expansion in the 
lung (39). This occurs just prior to peripheral T cell deletion and anergy, which is a noted 
outcome of enterotoxin T cell response (43, 44). The change in lung permeability was 
further accompanied by increased levels of soluble CD54, angiopoietin-2 and RAGE (Fig. 4-
1, D), increased expression of caspases (Fig. 4-2) and elevated cytokines and chemokines 
in BAL fluid (Fig. 4-3). At 40 h after SEA inhalation, the onset of the second phase was 
marked by changes in signaling events and activation of different pulmonary cell populations 
(Fig. 4-5). In particular, pSTAT5 expression was increased in T cells and NK cells (Fig. 4-5, 
G and J), whereas pSTAT3 expression was increased in dendritic cells and alveolar 
macrophages (Fig. 4-5, H and K). We posit that STAT5 phosphorylation is in response to T 
cell release of IL-2, while IL-6 release from innate cells promotes STAT3 phosphorylation 
(203). On the other hand, endothelial cells upregulated Icam-1 and downregulated Nos3 
transcription (Fig. 4-6, A), suggesting a loss of homeostatic mechanisms and polarization 
toward a more activated phenotype (190, 205). Finally, this later effect likely portended the 
reduction of endothelial cells, which also coincided with increased CD54 and CD95 
expression (Figs. 2-6, B and D). Thus, lung endothelial cells became activated and later 
began to disappear, probably by a death process, as S. aureus enterotoxin induced T cell 
activation and expansion.  
Taken together, these findings suggested a two-hit mechanism of endothelial cell 
injury: firstly, pulmonary endothelial cells became activated (Figs. 4-5, F and 4-6, A) due to 
early inflammatory responses occurring systemically or locally, but the endothelial barrier 
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remained intact throughout this phase (Fig. 4-1). More specifically, the massive levels of 
serum cytokines detected at 4 h (Fig. 4-3) or the transiently recruited neutrophils in the lung 
(30) could activate the endothelial cells without invoking their injury or death. A second hit, 
coinciding with the systemic and intrapulmonary expansion of SEA-specific T cells, induced 
the endothelial cells to downregulate homeostatic factors and acquire a more activated and 
death-prone phenotype, eventually leading to cellular dysfunction and death. Recently, it 
was proposed that sequential hits to the lung from various insults, such as pneumonia, 
sepsis, or mechanical ventilation may cause the severe pathology of ARDS. This proposed 
model for disease etiology and progression is known as the “multiple hit theory” (8). 
Similarly, animal models of ALI that consist of two inflammatory insults to the lung may 
better mimic the clinical scenario (206).  
 To unravel the mechanism responsible for the observed increase in pulmonary 
permeability, we designed our experimental strategy based on recent data showing that the 
early inflammatory responses were differentially affected by blocking TNF or CD28 
costimulation (183). In the current report, we demonstrate that TNF or CD28 blockade 
elicited a profound reduction of albumin in BAL fluid as well as diminished inflammation and 
expression of injury markers in the lung (Fig. 4-7). Thus, although there were no changes in 
pulmonary permeability initially (Fig. 4-1), early blockade of T cell activation reduced the 
subsequent lung injury. Consistent with the two-hit injury model, these findings suggested 
that the activation of endothelial cells due to an initial inflammatory stimulus may not 
necessarily induce their injury and death but may increase their sensitivity to secondary 
injury. 
           Understanding that the initial T cell activation influences lung injury at later time 
points is undoubtedly important; however, it may be difficult to translate these findings into 
clinical care, since delivering early therapy during the initial insult is often not possible. 
Previous studies attempting to reduce the inflammatory response after S. aureus enterotoxin 
inhalation administered therapy prophylactically or immediately after toxin exposure (207-
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210). Alternatively, we sought a therapeutic approach to reduce S. aureus enterotoxin-
induced lung injury in a scenario mimicking a clinical setting wherein enterotoxin inhalation 
preceded initiation of therapy by many hours. Because CD95 and CD54 were upregulated 
on endothelial cells after SEA inhalation (Fig. 4-6, D), we administered blocking antibodies 
targeting CD178 and CD54 at 36 h post-SEA. Previous studies found that both CD95 and 
CD178 were elevated in BAL fluid of ALI/ARDS, and the CD95/CD178 pathway may be 
critical for inducing epithelial cell injury (86, 192, 211, 212). However, with the exception of 
increasing lung neutrophil numbers (Fig. 4-8, E), blocking CD178 had no effect on lung 
injury measures in our model (Fig. 4-8, B-D). In sharp contrast, CD54 blockade profoundly 
reduced pulmonary injury, by means of decreasing BAL fluid cell number, preventing 
increases in proinflammatory cytokine release, minimizing expression of markers of 
endothelial and epithelial cell damage, and reducing lung permeability (Fig. 4-8). Being a 
costimulatory molecule, CD54 is expected to inhibit T cell activation at the time of antigen 
presentation (213-216), but our results show that many hours after SEA-induced activation, 
CD54 plays an active role in shaping T cell responses. In particular, specific T cell numbers 
were significantly reduced after CD54 therapy (Fig. 4-8, E). In addition to reducing T cell 
expansion in lung, another proposed mechanism by which CD54 blockade might maintain 
the lung barrier is based on data showing that CD54 was important for enhancing cytotoxic 
function of lymphocytes (194, 217, 218). Similarly, we observed substantial reductions in 
granzyme B and IFNγ in the BAL fluid of anti-CD54-treated mice (Fig 2-8, D). Intriguingly, 
there was no difference in the cytotoxic potential of SEA-specific CD8+ T cells after CD54 
therapy (Fig. 4-8, G), suggesting effector T cell differentiation was not markedly impaired. 
Rather than the synthesis, anti-CD54 therapy could be involved in regulating the release of 
cytotoxic and inflammatory molecules (196).  Finally, although SEA-induced lung injury is T 
cell-dependent (Fig. 4-2), other cell populations, including inflammatory innate cells are 
recruited to lung (Fig. 4-1, C). Therefore, anti-CD54 could also ameliorate the SEA-induced 
lung injury by affecting other cell types, such as neutrophils and monocytes. Although 
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recruitment of neutrophils and monocytes to lung was no affected by anti-CD54 (Fig. 4-2, E), 
the treatment could affect the function of these cells, such as reactive oxygen species 
production (219). CD54-targeted therapy was previously shown to attenuate pulmonary 
damage in two models of neutrophil-dependent lung injury (220, 221) and anti-CD54 
antibody (enlimomab) has already been tested in several clinical trials (e.g. transplantation, 
burn injuries and refractory rheumatoid arthritis) (222-224). Therefore, anti-CD54 may be a 
potential therapeutic target for ALI/ARDS worthy of further investigation. Finally, taking into 
account the role of CD54 in leukocyte migration during injury or infection (197), it will be 
important to accurately define therapeutic windows for CD54-blocking therapies given to 
ALI/ARDS patients. Furthermore, determining the molecular players downstream of CD54 
engagement may also enable development of more targeted treatment options. 
 The utility of CD54 therapy is well matched to a typical ALI clinical scenario. A patient 
suffering from a severe pneumonia or trauma may experience over-activation of the immune 
system and/or direct damage to the tissue, resulting in impaired lung barrier defenses. This 
deficit may predispose the patient to additional insults such as toxins and danger- and 
pathogen-associated molecular patterns that can give rise to systemic inflammatory 
response syndrome and/or ALI with T cells likely playing a crucial role (225). An excellent 
example is the appreciation of S. aureus enterotoxins in septic patients (79-81). Here, S. 
aureus enterotoxin inhalation was found to induce sequential changes in the lung, defined 
by initial rapid endothelial cell activation coinciding with inflammatory responses due to T 
cell priming followed by pulmonary injury and cell death coinciding with T cell expansion in 
the lung. Importantly, even when administered therapeutically at time points well beyond the 
inciting inflammatory trigger, anti-CD54 effectively reduced all measures of lung 
inflammation and injury and restored pulmonary barrier integrity. Thus, an 
immunotherapeutic agent targeting CD54 pathway may be a suitable treatment option for 
ALI/ARDS patients, especially in suspected cases of T cell-induced inflammation. 
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FIGURE 4-1: SEA increases pulmonary permeability, cellular recruitment and 
expression of epithelial and endothelial markers of injury 2 days after inhalation. A) 
Permeability in the lung was measured by FITC-dextran fluorescence assay. In the left 
panel, FITC-dextran was administered i.n. and serum was obtained 1 h later (24 and 48 h 
after SEA or vehicle inhalation). FITC fluorescence was measured in serum and normalized 
to the vehicle control. At least 3 independent experiments with n=8-11 per group. In the right 
panel, FITC-dextran was administered i.v. and BAL fluid was obtained 1 h later (48 h after 
SEA or vehicle). FITC fluorescence was measured in BAL fluid and normalized to vehicle 
control. Two independent experiments with n=6-10 per group. B) Concentration of albumin 
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in BAL fluid 24 and 48 h after SEA or vehicle inhalation. Three independent experiments 
with n=5 per group. C) Representative confocal microscopy images of lung tissue showing 
clusters of recruited myeloid cells (CD11b+ 7/4+) and SEA-specific T cells (Vβ3+) in proximity 
to macrophages (CD169+) 48 h after SEA inhalation. B = bronchiole, V = blood vessel. Scale 
bar = 80 µm. Images are representative of 3 independent experiments with n=4 for vehicle 
and n=6 for SEA. D) Concentration of the lung injury markers CD54, angiopoietin-2 and 
RAGE in BAL fluid 24 and 48 h after SEA or vehicle inhalation. Three experiments with n=5-
8 per group. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test or 
unpaired t test ( for Fig. 1A, right panel); **p<0.01, ***p<0.001. 
 	 79	
 
FIGURE 4-2: SEA induces apoptosis in the lung in a T cell-dependent manner. A) 
Number of BAL fluid cells and the concentration of albumin and angiopoietin-2 (ang-2) in 
BAL fluid 48 h after SEA or vehicle inhalation in WT and TCR βδ−/− mice. Two independent 
experiments with total n=6 per group. B) Apoptosis in the lung and spleen of WT and TCR 
βδ−/− mice 54 h after SEA or vehicle inhalation as measured by a pan-caspase-binding 
fluorescent probe. After injecting the probe i.v., tissue was removed and scanned by a 
fluorescence imager. C) Quantification of the pan-caspase-binding fluorescent probe in the 
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lung and spleen of WT and TCR βδ−/− mice 54 h after SEA or vehicle inhalation. Three 
independent experiments with n=8-18 mice per group. D) Representative confocal 
microscopy images of lung tissue showing the presence of apoptotic cells (active caspase-
3+) 48 h after SEA inhalation. Scale bar = 80 µm. The right panels depict magnified images 
of the fields indicated in the left panels. E) Number of active caspase-3+ cells per field. The 
number of positive cells 48 h after SEA or vehicle inhalation was determined from 3 images 
per mouse using Imaris (Bitplane). Counts in the SEA mice were performed in areas of 
inflammation. Data are representative of 3 independent experiments with n=4 for vehicle 
and n=6 for SEA. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test or 
unpaired t test (for Fig. 2E); ***p<0.001. 
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FIGURE 4-3: There are differential patterns of cytokine and chemokine release in BAL 
fluid vs. serum after SEA inhalation. BAL fluid and serum were collected 4, 14, 24 and 48 
h after SEA or vehicle inhalation, and protein levels of various analytes were measured by 
multiplex immunoassay. Data were combined from 3 independent experiments with n=4-7 
per group. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test; **p<0.01, 
***p<0.001. 
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FIGURE 4-4: Gating strategy to identify lung cell populations using ViSNE maps. 
Lungs were obtained from mice 14 or 40 h after SEA or vehicle inhalation. Each sample was 
barcoded, stained with heavy metal-conjugated antibodies and analyzed by mass cytometry 
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(Helios, Fluidigm). Data were debarcoded, and samples were further subgated to include 
33,000 cells and merged to generated the ViSNE maps (Matlab). The VisNE maps identify 
clusters of cells that are generated according to marker expression patterns.  Expression of 
each marker can be quantified based on the color gradient indicated on the left. The 
individual clusters in boxes in the periphery of figure 4 are phenotyped with known lineage 
markers and expression of the underlined marker is shown. The identity of each cluster is 
indicated in bold letters. Images are representative of 4 independent experiments.  
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FIGURE 4-5: Endothelial cells become activated prior to the appearance of lung 
pathology. Lung tissue was obtained from mice 14 or 40 h after SEA or vehicle inhalation. 
Individual samples were barcoded, pooled and then stained with heavy metal-conjugated 
antibodies. The pooled sample was analyzed by mass cytometry (Helios, Fluidigm). ViSNE 
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maps generated using MATLAB were used to represent clusters of cells identified according 
to expression of markers used in the experiment.  Expression of each marker can be 
visualized based on the color gradient indicated on the left. A) ViSNE maps to identify CD3+ 
cells and subpopulations of CD3+ cells (SEA-specific CD45+CD3+CD8+Vβ3+ and 
CD45+CD3+CD4+Vβ3+ T cells and bystander CD45+CD3+CD4+Vβ14+ T cells). B) Histograms 
showing the expression of signaling and activation markers in T cells 40 h after vehicle 
(blue) vs. SEA (red) inhalation. C) ViSNE maps identifying dendritic cells 
(CD45+CD11c+MHC II+). D) Histograms showing the expression of signaling and activation 
markers in dendritic cells 14 (top panel) or 40 h (bottom panel) after vehicle (blue) vs. SEA 
(red) inhalation. E) ViSNE maps identifying endothelial cells (CD45−CD31+CD54+). F) 
Histograms showing the expression of signaling and activation markers in endothelial cells 
14 (top panel) or 40 h (bottom panel) after vehicle (blue) vs. SEA (red) inhalation. G) pSTAT 
median intensity (MI) in T cell populations 40 h after SEA or vehicle inhalation. H) pSTAT3 
median intensity in dendritic cells 14 or 40 h after SEA or vehicle inhalation. I) MHC II 
median intensity in endothelial cells 14 or 40 h after SEA or vehicle inhalation. J) pSTAT5 
median intensity in CD45+NK1.1+CD3− NK cells 40 h after SEA or vehicle inhalation. K) 
pSTAT3 median intensity in CD45+CD11c+SIGLEC F+ alveolar macrophages 40 h after SEA 
or vehicle inhalation. Each experiment is represented as a pair of connected symbols (blue 
square = vehicle; red square = SEA) with a mean shown as a horizontal line. Data are 
representative of 4 independent experiments with n=4 per group. Paired t test; *p<0.05, 
**p<0.01.  
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FIGURE 4-6: SEA inhalation causes both early and late changes in endothelial cells. 
A) Endothelial cell gene expression 14, 24, or 40 h after vehicle or SEA inhalation. 
Endothelial cells (CD45−CD31+CD54+) were then sorted from total lung cells and lysed to 
obtain RNA. Gene expression levels are normalized to Gapdh and shown relative to vehicle 
control (set to 1). Three independent experiments with n=6 per group. B) Number of lung 
endothelial cells (ECs; CD45−CD31+) 48 h after SEA or vehicle inhalation as measured by 
flow cytometry. C) Correlation between endothelial cell and CD3+Vβ3+ T cell percentages in 
the lung 48 h after SEA inhalation. Linear regression curve fit p value was calculated via F 
test. Two independent experiments with n=8 per group. D) Expression of surface CD54 and 
CD95 on endothelial cells (CD45−CD31+) 48 h after SEA or vehicle inhalation. E) Surface 
expression of CD11a and CD95 and intracellular expression of granzyme B (Gzm B) in 
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CD3+Vβ3+ T cells 48 h after SEA or vehicle inhalation. Histograms are representative of 2 
independent experiments with n=8 per group. Median fluorescent intensities in the upper 
corner of each histogram are shown as average ± SD of 1 out of the 2 experiments. Isotype 
control (gray), vehicle = V (black dashed line), SEA = S (black thick line). F) Granzyme B 
concentration in BAL fluid of SEA or vehicle-treated mice 24 and 48 h after inhalation. Three 
independent experiments with n=8 per group. Data are represented as mean ± SEM. Two-
way ANOVA with Sidak’s test or unpaired t test (for Fig. 5B); *p<0.05, **p<0.01, ***p<0.001. 
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FIGURE 4-7: Blocking T cell activation with CTLA4-Ig or anti-TNF in part attenuates 
measures of lung permeability, cell injury and inflammation after SEA inhalation. A) 
Diagram of experimental set-up. Mice were treated with CTLA4-Ig, anti-TNF or IgG control 2 
h prior to SEA inhalation. BAL fluid and lung tissue were obtained 48 h after SEA inhalation. 
B) Total number of BAL fluid cells pre-treated with IgG control, CTLA4-Ig, or anti-TNF as 
described in “A”. C) Composition of cells within the BAL fluid following IgG control, CTLA4-
Ig, or anti-TNF pre-treatment. Average percentages of CD45+CD3+Vβ3− T cells, 
CD45+CD3+Vβ3+ T cells, neutrophils (CD45+CD11b+Ly6C+Ly6G+) and monocytes 
(CD45+CD11b+Ly6C+Ly6G−) in BAL fluid are represented by stacked bars. D) 
Concentrations of injury markers angiopoietin-2 (ang-2), RAGE, CD54), inflammatory 
markers granzyme B (gzm B), IFNγ, IL-6, and TNF, and albumin in BAL fluid from mice pre-
treated with IgG control, CTLA4-Ig, or anti-TNF. E) Total number of Vβ3+ T cells, monocytes 
and neutrophils in lung in mice pre-treated with IgG control, CTLA4-Ig, or anti-TNF. Data are 
represented as mean ± SEM. Three independent experiments with n=9 per group. One-way 
ANOVA with Dunnett’s test; *p<0.05, **p<0.01, ***p<0.001. 
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FIGURE 4-8: Delayed CD54 blockade substantially minimizes lung permeability, cell 
injury and inflammation after SEA inhalation. A) Diagram of experimental set-up. Mice 
were administered SEA i.n., then they were treated with IgG control, anti-CD178 or anti-
CD54 i.p 36 h later. BAL fluid and tissue were obtained 48 h after SEA inhalation. B) Total 
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number of BAL fluid cells from mice treated with IgG control, anti-CD178, or anti-CD54 as 
described in “A”. C) Composition of cells within the BAL fluid following IgG control, anti-
CD178, or anti-CD54 treatment. Average percentages of CD45+CD3+Vβ3− T cells, 
CD45+CD3+Vβ3+ T cells, neutrophils (CD45+CD11b+Ly6C+Ly6G+) and monocytes 
(CD45+CD11b+Ly6C+Ly6G−) in BAL fluid are represented by stacked bars. D) 
Concentrations of injury markers angiopoietin-2 (ang-2), RAGE, and CD54, inflammatory 
markers granzyme B (gzm B), IFNγ, IL-6, and TNF, and albumin in BAL fluid from mice 
treated with IgG control, anti-CD178, or anti-CD54. E) Total number of Vβ3+ T cells, 
monocytes and neutrophils in lung in mice treated with IgG control, anti-CD178, or anti-
CD54. Three independent experiments with n=9 per group. F) Lung permeability measured 
by FITC-dextran permeability assay. Mice were given SEA or vehicle i.n. and the SEA-
exposed mice were treated with IgG control or anti-CD54 36 h later. FITC-dextran was 
administered i.v. 1 h prior to sacrifice. FITC fluorescence was measured in BAL fluid and 
normalized to IgG-treated mice. Data were combined from 3 independent experiments with 
n=7-11. G) The expression (median fluorescent intensity = MFI) of granzyme B and IFNγ in 
CD8+Vβ3+ T cells (CD45+CD3+CD8+Vβ3+). The lung cells were cultured with brefeldin A only 
(granzyme B) or brefeldin A + PMA/ionomycin (IFNγ) for 5 h and stained with antibodies. 
Two independent experiments with total n=6-8 per group. Data are shown as mean ± SEM. 
One-way ANOVA with Dunnett’s test (for Fig. 4-8, B-E) or One-way ANOVA with Tukey’s 
test (for Fig. 4-8, F and G); *p<0.05, **p<0.01, ***p<0.001. 
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Chapter 5: Alveolar Macrophages in S. aureus Enterotoxin A-Mediated 
Inflammation  
 
The findings of this chapter were published in ImmunoHorizons, vol. 1, issue 9, pp. 213-222, 
November 1, 2017 under the title “CD169+ macrophages restrain systemic inflammation 
induced by Staphyloccocus aureus enterotoxin A lung response.” The article was written by 
Julia Svedova, Antoine Ménoret, Stephen T. Yeung, Masato Tanaka, Kamal M. Khanna, 
and Anthony T. Vella. 
 
Abstract 
Alveolar macrophages (AMs) are considered the first line of defense in the airways. 
Exposure to harmful substances and certain infections can lead to dysfunction or depletion 
of AMs. Importantly, these conditions have been associated with increased risk of sepsis 
and acute lung injury. Staphylococcus aureus enterotoxins are superantigens that induce 
oligoclonal activation of T cells and a robust cytokine release, leading to systemic 
inflammatory response and tissue injury. This study investigated the relationship between S. 
aureus enterotoxins and AMs. Following inhalation, S. aureus enterotoxin was preferentially 
bound to AMs and the binding was independent of MHC II. Furthermore, the enterotoxin 
was internalized and its presence in the cells decreased by 24 h after exposure. Ablation of 
AMs in CD169-DTR mice was associated with increased activation of enterotoxin-specific T 
cells and enhanced cytokine release into circulation. Thus, conditions causing depletion of 
AMs may increase the risk of S. aureus enterotoxin-induced diseases.  
 
Introduction 
Alveolar macrophages (AMs) are specialized tissue-resident cells that play a crucial 
role in lung development, homeostasis, and immune surveillance. Their unique position in 
the lung alveoli enables them to sample pathogens, inhaled particulates and other 
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environmental cues. Their reciprocal interactions with neighboring cells through various 
receptors and cytokine/chemokine axis can then alarm the immune system and orchestrate 
responses to remove potential threats and respond to tissue injury, making them the first 
line of pulmonary immune defense (226, 227). AMs have been shown to play a critical anti-
inflammatory role in a number of disease animal models, including influenza, asthma, and 
acute lung injury (228-233) but they could be also pro-inflammatory (234, 235).  
AMs are a relatively stable population of cells with very slow turnover rate; however, 
if the injury is severe enough, AMs may be depleted and later replenished from circulating 
monocytes or from in situ proliferation (226, 227). Exposure to various substances, 
pathogens and their products may lead to AM depletion or impaired function; these include 
influenza (236), bacterial pneumonia (237) cigarette smoke (238), anesthesia (239), 
diabetes (240), or alcohol consumption (241). Importantly, many of these conditions or 
exposures have been associated with increased risk of serious infections and development 
of systemic inflammatory response syndrome (SIRS)/sepsis and acute respiratory distress 
syndrome (ARDS). In particular, influenza can be complicated by a secondary bacterial 
pneumonia, which leads to higher rates of hospitalization and death (242). Increased alcohol 
consumption and cigarette smoke exposure have been associated with increased risk of 
SIRS/septic shock and ARDS, respectively (243-246). Finally, a number of chronic 
conditions, particularly diabetes mellitus, and immunosuppressive state are well-described 
comorbidities in sepsis patients (7, 72, 247). Altogether, these studies suggest that depletion 
or impaired function of AMs may be associated with increased risk of serious infection, 
sepsis and ARDS.  
Staphylococcus aureus enterotoxins are a group of potent bacterial toxins that 
bypass the classical antigen processing and presentation, directly bind to MHC II on 
antigen-presenting cells and crosslink it with specific Vβ chains of T cell receptors. This 
unique feature of the so-called superantigens induces a massive inflammatory response 
marked by oligoclonal T cell activation and cytokine storm (10, 111). Superantigens have 
 	 93	
been established as the mediators of toxic shock syndrome, a type of systemic inflammatory 
response, which can lead to tissue injury, shock and even death (9, 36). However, recent 
evidence suggest that they may be involved in a number of diseases, including pneumonia, 
endocarditis, and sepsis (9, 85, 96, 177). In fact, superantigens and superantigen-
expressing S. aureus strains have been recovered from septic patients (79-81). S. aureus 
enterotoxins likely spread systemically from focal sites of infection rather than being directly 
produced in the bloodstream, as hemoglobin peptides were shown to inhibit superantigen 
production (9, 99, 100). The most common colonization site of S. aureus is the anterior 
nares (11); therefore, exposure to aerosolized or inhaled S. aureus enterotoxin may well 
mimic the route of dissemination. Accidental exposure to aerosolized S. aureus enterotoxin 
in humans was reported to cause systemic symptoms of fever, chills, headache, myalgia, 
cough, dyspnea, vomiting and diarrhea in humans (104). In non-human primates, 
aerosolized lethal doses of S. aureus enterotoxin caused severe pulmonary lesions and 
death in some subjects (98). Finally, S. aureus enterotoxin inhalation in mice was shown to 
cause systemic inflammatory response, involving rapid activation of T cells, cytokine 
release, recruitment of innate cells and subsequent lung injury (34, 39, 183).  
 The relationship between AMs and S. aureus enterotoxins has not been fully 
explored. In vitro stimulation of human AMs with S. aureus enterotoxin A (SEA) induced IL-8 
production in a dose-dependent manner (248). In another in vitro study, addition of 
macrophages (AMs or peritoneal macrophages) reduced proliferation of SEA-activated T 
cells via nitric oxide production (249). Although there is only a limited direct link between 
AMs and S. aureus enterotoxins, indirect evidence exists that shows a relationship between 
superantigens and conditions that deplete AMs. In particular, several reports from the 1980s 
described development of toxic shock syndrome in patients with influenza and influenza-like 
illness (250, 251). Furthermore, a recent study showed that the combination of cigarette 
smoke exposure and S. aureus enterotoxin B (SEB) induced greater extent of pulmonary 
inflammation than cigarette smoke or SEB alone (252). Based on these findings, we 
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hypothesized that AMs play a critical role in the inflammatory responses triggered by S. 
aureus enterotoxin inhalation.  
Here we show that SEA was taken up by AMs upon inhalation and the enterotoxin 
was found intracellularly and not on cell surface. Perhaps surprisingly, this binding was 
independent of MHC II expression as SEA was similarly taken up by AMs of WT and MHC 
II−⁄− mice. AMs in the murine lung express sialoadhesin, also known as CD169 on their 
surface (229, 253). Thus, to study the role of AMs, CD169-diphteria toxin receptor (DTR) 
mice were treated with diphtheria toxin (DT) and then exposed to SEA. The absence of AMs 
was associated with increased CD25 expression on SEA-specific T cells but this effect was 
only observed when lower concentrations of SEA were administered. Finally, SEA-exposed 
CD169-DTR mice also showed a significantly greater cytokine secretion to blood compared 
to WT mice. Thus, AMs may represent a defense mechanism against S. aureus 
enterotoxins as their depletion may increase the severity of toxic shock or other S. aureus 
enterotoxin-induced diseases.  
 
Results 
 
S. aureus enterotoxin preferentially binds to alveolar macrophages in MHC II-
independent manner 
One of the crucial properties of S. aureus enterotoxins is their ability to rapidly induce 
oligoclonal activation of T cells, which is accompanied by a massive inflammatory response 
and cytokine storm (10). However, how SEA and other enterotoxins spread systemically, 
especially from the airways as anterior nares are a common site of S. aureus colonies (11) 
is not fully understood. In our previous studies we uncovered that SEA permeates into blood 
immediately after inhalation and is found in the serum rather than bound to cells (183). The 
ability to access circulatory system from airway mucosa is likely an important feature that 
enables the toxin to spread systemically and activate T cells in lymphoid tissues within 
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minutes of inhalation (30, 183). Furthermore, using a titration curve, the concentration of 
SEA in serum after inhalation was estimated to be only a small fraction of the total amount 
inhaled by a mouse (~ less than 1/35; unpublished data shown in Fig. 3-2). Intriguingly, in 
another report using mass spectrometry, we showed that SEA could be recovered from BAL 
fluid at 16 h after inhalation and the toxin preserved its biological activity (254). These 
findings suggested that when SEA is inhaled, only a small portion enters the circulation 
while the remainder may be retained in the lung mucosa or perhaps neutralized by various 
defense mechanisms, such as defensins or phagocytosis.  
Therefore, we sought to determine whether SEA binds to a certain cell population 
within the pulmonary tissue. Lung was obtained from mice 8 h after SEA or vehicle 
inhalation and examined by confocal microscopy for SEA using polyclonal anti-SEA 
antibody. Only mice exposed to SEA displayed cells that were SEA+ (Fig. 5-1, A and B), 
confirming the specificity of the antibody. Surprisingly, it was found that SEA was 
preferentially bound to CD11c+CD169+ AMs (Fig. 5-1, A). In fact, a total of 87% of SEA+ 
cells were also positive for CD11c and 64% were both CD11c+ and CD169+ (Fig. 5-1, C). To 
further define SEA binding to AMs, BAL fluid was obtained from mice 1, 4, or 24 h after SEA 
inhalation and BAL AMs defined as CD45+CD11c+SIGLEC F+CD169+ (Fig. 5-1, D) were 
stained for SEA. Importantly, no SEA was detected on the surface of AMs; however, there 
was a significant increase in SEA presence intracellularly peaking at 4 h (Fig. 5-1, E and F). 
Interestingly, there was no significant difference detected at 24 h after SEA (Fig. 5-1, F). 
Similar results were obtained when AMs from lung tissue were analyzed (Fig. 5-2, A). In 
contrast, lung dendritic cells showed increased SEA expression only at 24 h both on the 
surface and intracellularly (Fig. 5-2, B).  
S. aureus enterotoxins are known for their ability to directly bind to MHC II molecules 
and crosslink them with specific Vβ chains of TCRs leading to a systemic inflammatory 
response (10). However, AMs were reported to only express low levels of MHC II under 
homeostatic conditions (226, 255) with MHC II expression increasing during an inflammatory 
 	 96	
response, particularly in the presence of IFNγ (256). Furthermore, AMs tend to be poor 
antigen-presenters and may, in fact, inactivate T cells (257, 258). These findings suggested 
that SEA binding to AMs could be MHC II-independent. To assess whether SEA binds to 
AMs in MHC II-independent fashion, lung tissue was harvested from WT and MHC II−⁄− mice 
8 h after SEA inhalation and analyzed by confocal microscopy. There was no difference in 
the number of SEA+ cells between WT and MHC II−⁄− mice (Fig. 5-3, A and B). In addition, 
SEA+ cells colocalized with CD11c marker with a similar frequency (Fig. 5-3, C). Finally, only 
a small fraction of SEA+ cells colocalized with MHC II (Fig. 5-3, D) and in fact, we observed 
CD11c+MHC II+ dendritic cells with no significant SEA binding (Fig. 5-3, A, white arrows). 
Altogether, these results show for the first time that SEA binds to AMs in MHC II-
independent manner.  
 
Depletion of alveolar macrophages is associated with increased T cell activation and 
cytokine secretion  
Next, we wanted to determine whether SEA binding to AMs impacts T cell activation 
and cytokine production. We hypothesized that AMs sequester a large portion of the inhaled 
toxin and neutralize it. Thus, AMs could play a protective role in SEA-induced inflammation. 
To investigate the role of AMs in SEA-induced inflammatory response, we used CD169-DTR 
mice to selectively deplete CD169+ macrophages after DT administration. Because AMs 
express CD169 (Fig. 5-1), this technique can be used to study the role of AMs in pulmonary 
responses (229). Thus, CD169-DTR mice and WT control were treated with DT 2 days prior 
to SEA or vehicle inhalation. In order to avoid oversaturation of SEA dosage given to mice 
(which could lead to masking of differences between WT and CD69-DTR mice), the SEA 
dose was titrated (0.033, 0.1, 0.33, and 1 µg). Blood, lung and spleen were harvested 4 h 
after SEA or vehicle (0 µg) inhalation. Depletion of CD169+ alveolar macrophages was 
confirmed in the lung by gating on CD45+CD11c+SIGLEC F+CD169+ cells (Fig. 5-4, A). The 
overall depletion of AMs was approximately 87% (Fig. 5-4, B). We first investigated the 
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effect of CD169+ macrophage ablation on CD69 expression on SEA-specific Vβ3+ T cells in 
the spleen. Interestingly, even with a low dose of SEA (0.033 µg), the percentage of CD69+ 
Vβ3+ T cells was 88.5% in WT mice and 89.8% in CD169-DTR mice, suggesting that a very 
small amount of SEA is sufficient to induce CD69 expression on T cells (Fig. 5-4, C and D). 
Thus, we concluded that CD69 expression might not be a sensitive marker to detect 
differences in T cell activation. In contrast, CD25 expression on Vβ3+ T cells increased in a 
dose-dependent manner (Fig. 5-4, F). Importantly, CD169-DTR mice showed significantly 
greater percentage of CD25+ Vβ3+ T cells when 0.033 and 0.1 µg of SEA was administered 
(Fig. 5-4, E and F). There was no significant effect on CD25 expression with the higher 
doses of SEA (0.33 or 1 µg; Fig. 5-4, F). We also investigated the effect of AM ablation on 
the bystander Vβ14+ T cells. There was no difference in the percentage of CD69+ and 
CD25+ of Vβ14+ T cells with the exception of a significant increase in CD25+ Vβ14+ T cells in 
CD169-DTR mice after a dose of 0.033 µg SEA (Fig. 5-4, D and F, right panels). 
A hallmark of toxic shock syndrome as well as sepsis is a robust release of cytokines 
into the bloodstream (36, 259). Therefore, we next investigated whether the depletion of 
CD169+ macrophages affected cytokine secretion following SEA inhalation. Serum cytokine 
concentrations were measured by a multiplex assay in DT pre-treated WT and CD169-DTR 
mice 4 h after vehicle or SEA  (0.033 or 0.1 µg) inhalation. There was no significant 
difference in the levels of serum cytokine when vehicle control was administered. However, 
following SEA inhalation, CD169-DTR mice had greater concentrations of serum G-CSF, 
IFNγ, TNF, IL-2, IL-6, and also IL-10 compared to WT mice (Fig. 5-5). These findings show 
that ablation of AMs is associated with increased expression of CD25 on SEA-specific Vβ3+ 
T cells and also increased secretion of cytokines into the circulation.  
 
Discussion 
Superantigens such as S. aureus enterotoxins are potent bacterial toxins that can 
induce serious inflammatory responses and lethal shock (10). It has been estimated that 
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most strains of S. aureus are capable of producing superantigens (9, 260). However, S. 
aureus is also an extremely common commensal that permanently colonizes about 20% of 
all individuals (11). Thus, there is a disparity in understanding why S. aureus is so common 
in asymptomatic individuals and simultaneously, it can trigger a life-threatening inflammatory 
response. Although the mechanisms of how a commensal colonization can become 
pathogenic are not clear (260), it has been well established that patients who have 
colonization of anterior nares with S. aureus and particularly methicillin resistant S. aureus 
(MRSA) are more susceptible to hospital-acquired S. aureus infections (101-103). This 
suggests that various defense mechanisms must be in place to prevent the spread of the 
bacteria and limit the effects of the virulence factors; however, these mechanisms may be 
impaired in immunocompromised individuals in hospital settings.  
Indeed, the immune system possesses several strategies to counteract the harmful 
effects of superantigens. First, It has been hypothesized that the production of antibodies 
against superantigens is protective and the lack of antibodies may a predisposing factor for 
the development of S. aureus infections and toxic shock syndrome (261-263). In particular, 
women with toxic shock syndrome had lower antibody titers to TSST-1 compared to healthy 
women with no prior history of toxic shock syndrome (262). Similarly, immunotherapy using 
antibodies specific to superantigens was found to be protective in animal models (264-266). 
In addition to antibodies, it has been shown that lactoferrin, an iron-binding glycoprotein 
located predominantly in mucosal secretions (267), can attenuate the inflammatory 
responses triggered by S. aureus enterotoxins (254, 268). Here we show that AMs may 
represent a key cellular defense mechanism that can reduce the effects of S. aureus 
enterotoxin-induced inflammation.  
When staining for SEA in the lung tissue, we found that AMs preferentially bound 
SEA after inhalation and internalized it (Fig. 5-1). Interestingly, the intracellular presence of 
SEA in AMs increased in the first several hours but was not significantly different at 24 h 
(Fig. 5-1, F and 5-2, A). In addition, dendritic cells, which were hypothesized to bind a 
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significant amount of SEA due to their high MHC II expression, showed upregulation of SEA 
expression on surface and intracellularly only at 24 h after inhalation (Fig 5-2, B). Based on 
these findings, we postulate that the numerous and highly phagocytic AMs ingest SEA and 
thus reduce the ability of dendritic cells either in the lung mucosa or in other tissues to take 
up the antigen and present it. In fact, AMs have been shown to maintain the lung 
homeostasis by suppressing dendritic cell function (269, 270). The later presence of SEA on 
pulmonary dendritic cells could perhaps be due to antigen transfer from AMs to dendritic 
cells (271). 
Superantigens, such as S. aureus enterotoxins, are known for their ability to bind to 
MHC II directly without antigen processing, which results in rapid oligoclonal activation of T 
cells and a cytokine storm (10). In addition, compared to SEB, SEA was found to have a 
greater affinity for MHC II due to its ability to not only bind the α chain but also the β chain of 
MHC II with a zinc-dependent binding site, which enabled SEA to stay on cell surface for at 
least 40 h (26). Interestingly, we found that the binding of SEA to AMs was independent of 
MHC II expression (Fig. 5-3). Binding of S. aureus enterotoxins to molecules other than 
MHC II have been previously reported. In particular, the costimulatory molecule CD28 and 
its ligand CD86 are crucial binding sites that enhance the severity of the inflammatory 
response triggered by S. aureus enterotoxin (27-29). Other binding sites for S. aureus 
enterotoxins have been reported, including MHC I (272), digalactosylceramide on kidney 
proximal tubular cells (273) and Gp130 receptor on adipocytes (274). These studies show 
that S. aureus enterotoxins may bind to several different molecules. Thus, it will be 
important to determine the identity of the binding site of SEA on AMs as well as the 
processing of the enterotoxin by these phagocytes.  
Previous studies showed that following intranasal S. aureus enterotoxin exposure, 
mice experience a systemic oligoclonal T cell activation and cytokine release to blood (23, 
34, 183, 275). To examine the role of AMs in the SEA-induced inflammatory response, WT 
and CD169-DTR mice were treated with DT and 2 days later, they were exposed to vehicle 
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or SEA. There was no difference in the expression of activation markers CD25 or CD69 on 
SEA-specific Vβ3+ T cells as well as no significant change in serum cytokines when mice 
were administered vehicle control (Fig. 5-4 and 5-5). However, CD169-DTR exposed to SEA 
showed a significantly greater CD25 expression compared to WT mice (Fig. 5-4, F). This 
was only observed when lower amounts of SEA were given, suggesting that the higher 
doses of SEA saturate the level of T cell activation. Indeed, even 0.033 µg of SEA activated 
almost 90% of SEA-specific Vβ3+ T cells in the spleen (Fig. 5-4, F). These findings 
emphasize the potency of SEA, which even in a small amount is sufficient to trigger a 
significant response. Furthermore, we examined the concentrations of serum cytokines 
commonly associated with toxic shock syndrome and sepsis, in particular, TNF, IFNγ, IL-2, 
and IL-6 (36, 75, 259). IL-10 and G-CSF were also analyzed. G-CSF, a growth factor that 
mobilizes neutrophils into circulation during acute inflammation (128), was previously found 
elevated in patients with bacterial infection (276, 277) while the anti-inflammatory cytokine 
IL-10 can be released in septic patients in attempt to counteract the hyper-inflammatory 
response (259). Importantly, SEA-exposed CD169-DTR mice had increased secretion of 
pro-inflammatory cytokines TNF, IFNγ, IL-2, IL-6 as well as G-CSF demonstrating that AM 
ablation is associated with enhanced inflammatory response following SEA inhalation (Fig. 
5-5). Interestingly, the concentration of anti-inflammatory IL-10 was also elevated in CD169-
DTR mice (Fig. 5-5). This is consistent with our previous study showing that SEA 
simultaneously induced the expression of both pro-inflammatory cytokines IL-2, TNF, and 
IFNγ and anti-inflammatory IL-10 in SEA-specific Vβ3+ T cells (183). Thus, depletion of AMs 
was correlated with an overall enhancement of the SEA-induced immune response.  
Finally, CD169 is expressed not only on AMs but also other macrophages, including 
marginal zone macrophages in the spleen and subcapsular sinus macrophages in the LNs 
(278, 279). Therefore, depletion of macrophage subsets other than AMs could also 
contribute to the enhanced inflammatory response observed in CD169-DTR mice. Similarly, 
it is also possible that DT injection and the subsequent cell apoptosis could play a role in the 
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increased inflammatory response in CD169-DTR mice. Therefore, further studies will be 
necessary to confirm the causal relationship between AMs and S. aureus enterotoxin-
induced systemic inflammatory response. 
In conclusion, here we show that AMs preferentially bind S. aureus enterotoxin in 
MHC II-independent manner and internalize it. Furthermore, AM ablation in CD169-DTR 
mice was associated with increased activation of SEA-specific Vβ3+ T cells and enhanced 
secretion of cytokines into circulation. These findings could explain the development of toxic 
shock syndrome in patients with influenza infection (250, 251) as well as the increased risk 
of sepsis and ARDS in chronic alcohol users and smokers, respectively (243-246). Thus, 
dysfunction or depletion of AMs may be a critical risk factor for the development of S. aureus 
enterotoxin-induced inflammatory diseases.  
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FIGURE 5-1: SEA preferentially binds to AMs upon inhalation. A) Representative 
confocal microscopy images of lung tissue 8 h after SEA or vehicle inhalation. Lung sections 
were stained with anti-SEA (green), anti-CD11c (red), and anti-CD169 (blue). Magnified 
images of the areas marked by white squares in the overlay panels are shown on the left. 
Size bar = 80 µm. 4 independent experiments with total n=5 per group. B) Number of SEA+ 
cells per field. Three images from each mouse were quantified (4 independent experiments 
with n=5 per group) by Imaris (Bitplane). C) Percentage of CD11c+CD169+ and 
CD11c+CD169− cells in all SEA+ cells detected by confocal microscopy 8 h after SEA 
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inhalation. SEA+ cells were colocalized with CD11c+ cells and SEA+CD11c+ cells were 
further colocalized with CD169 by Imaris. The average percentage shown in the pie chart 
was calculated from 3 images per mouse (3 independent experiments with total n=4). D) 
Gating strategy to identify AMs in the BAL fluid by flow cytometry. BAL fluid was obtained 1, 
4, or 24 h after SEA inhalation or from vehicle control (1 or 4 h) and AMs were identified as 
live CD45+CD11c+SIGLEC F+CD169+ cells. E) Representative histograms showing SEA 
expression on surface and intracellularly in BAL fluid AMs. F) Relative median fluorescent 
intensity (MFI) of SEA on surface and intracellularly in BAL fluid AMs 1, 4, or 24 h after SEA 
inhalation. MFI values are relative to the vehicle control (set as 1). Three independent 
experiments with total n=7 per group. Data are represented as mean ± SEM. Unpaired t test 
(B) or one-way ANOVA with Dunnett’s test (F); *p<0.05, ***p<0.001. 
 
FIGURE 5-2: SEA presence in lung AMs and DCs. Lung tissue was harvested 1, 4, or 24 
h after SEA inhalation or from vehicle control (1 or 4 h). AMs were identified as live 
CD45+CD11c+SIGLEC F+CD169+ cells and DCs as live CD45+CD11c+SIGLEC F−MHC II+. 
A) Relative median fluorescent intensity (MFI) of SEA on surface and intracellularly in lung 
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AMs 1, 4, or 24 h after SEA inhalation. B) Relative MFI of SEA on surface and intracellularly 
in lung DCs 1, 4, or 24 h after SEA inhalation. MFI values are relative to the vehicle control 
(set as 1). Two independent experiments with total n=4 per group. Data are represented as 
mean ± SEM. One-way ANOVA with Dunnett’s test was used; *p<0.05, ** p<0.01, 
***p<0.001. 
 
FIGURE 5-3: SEA binding to AMs is MHC II-independent. A) Representative confocal 
microscopy images comparing SEA binding in WT and MHC II−⁄− mice 8 h after SEA 
inhalation. Lung sections were stained with anti-SEA (green), anti-CD11c (red), and anti-
MHC II (blue). Magnified images of the areas marked by white squares in the overlay panels 
are shown on the left. White arrows in the magnified panel (WT) point to dendritic cells 
(CD11c+MHC II+). Size bar = 80 µm. Three independent experiments with total n=5 per 
group. B) Number of SEA+ cells per field. Three images from each mouse were quantified (3 
independent experiments with n=5 per group) by Imaris (Bitplane). C) Percentage of CD11c+ 
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cells in all SEA+ cells detected by confocal microscopy 8 h after SEA inhalation. SEA+ cells 
in WT and MHC II−⁄− mice were colocalized with CD11c+ cells by Imaris (3 images per 
mouse; 3 independent experiments with n=5 per group). D) Percentage of MHC II+ cells in 
all SEA+ cells detected by confocal microscopy 8 h after SEA inhalation. SEA+ cells in WT 
mice were colocalized with MHC II+ cells by Imaris (3 images per mouse; 3 independent 
experiments with n=5 per group). Data are represented as mean ± SEM. Unpaired t test.  
 
 
FIGURE 5-4: Depletion of CD169+ cells leads to increased expression of CD25 on 
SEA-specific Vβ3+ T cells. WT and CD169-DTR mice received DT 2 days prior to SEA or 
vehicle inhalation. Lung and spleen were removed 4 h after vehicle (0 µg) or SEA (0.033, 
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0.1, 0.33 or 1 µg) inhalation. A) and B) Representative flow cytometry plots (A) and scatter 
dot plot (B) showing depletion of AMs in lung (gated as live CD45+CD11c+SIGLEC 
F+CD169+ cells) in CD169-DTR mice compared to WT mice. The percentage of AMs is 
relative to all live cells. C) Representative histogram of CD69 expression in live 
CD45+CD3+Vβ3+ cells in WT (black) and CD169-DTR (red) mice 4 h after 0.033 µg SEA 
inhalation. Gray = isotype control. D) Percentage of CD69+ cells in Vβ3+ (left) and Vβ14+ 
(right) T cells 4 h after 0, 0.033, 0.1, 0.33 or 1 µg of SEA inhalation. E) Representative 
histogram of CD25 expression in live CD45+CD3+Vβ3+ cells in WT (black) and CD169-DTR 
(red) mice 4 h after 0.033 µg SEA inhalation. Gray = isotype control. F) Percentage of 
CD25+ cells in Vβ3+ (left) and Vβ14+ (right) T cells 4 h after 0, 0.033, 0.1, 0.33 or 1 µg of 
SEA inhalation. The data were compiled from 3 independent experiments with total n=5-6 
per group. Two-way ANOVA with Sidak’s test; *p<0.05, **p<0.01, ***p<0.001. 
 
 
FIGURE 5-5: Depletion of CD169+ cells increases the concentration of serum 
cytokines after SEA inhalation. Serum was obtained from tail blood 4 h after vehicle (0 µg) 
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or SEA (0.033 or 0.1 µg) inhalation. The concentrations of different cytokines were 
measured by a bead-based multiplex assay (EMD Millipore). The data were compiled from 3 
independent experiments with total n=6 per group. Two-way ANOVA with Sidak’s test; 
*p<0.05, **p<0.01, ***p<0.001. 
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Chapter 6: Conclusions and Future Directions 
 
Together with previous reports (30, 34, 39, 106, 254), these studies demonstrated 
the intricate pathways employed in S. aureus enterotoxin-induced inflammation and the key 
findings are shown in Fig. 6.1 and Fig. 6.2. Fig. 6.1 depicts the early inflammatory 
responses following SEA inhalation; in particular, how SEA spreads systemically from the 
airways and how the activated adaptive immunity triggers the recruitment of innate immune 
cells to blood, LNs and lung. Fig. 6.2 shows the pulmonary responses leading to lung injury 
2 days after SEA inhalation. Although these findings uncovered various mechanisms in S. 
aureus enterotoxin-induced inflammation and potentially also in SIRS/sepsis and ALI/ARDS, 
there are several remaining questions. 
Firstly, it will be important to further investigate the role of innate immune cells, 
particularly neutrophils and monocytes, in S. aureus enterotoxin inflammatory response. 
Both chapter 3 and chapter 4 demonstrated that neutrophils and inflammatory monocytes 
are recruited to blood, lymphoid tissues and lung (183, 275). However, it is not currently 
clear whether the recruitment and activation of innate cells contributes to the severity of the 
response or actual tissue injury. Neutrophils and monocytes are considered the first line of 
immune defense in acute inflammatory response and their non-specific products, such as 
reactive oxygen species and proteolytic enzymes, are thought to be responsible for the 
host’s tissue injury (2-4). Thus, it will be important to determine to what extent the innate 
immune cells affect S. aureus enterotoxin-induced inflammatory response (e.g. in the T cell 
zone of the LNs following their recruitment) and cell damage (e.g. in the lung 2 days after 
inhalation). 
Secondly, the role of AMs in systemic inflammation following S. aureus enterotoxin 
exposure warrants further studies. The findings of chapter 5 unraveled an important 
relationship between AMs, SEA and the subsequent systemic inflammatory response. In 
particular, depletion of AMs was associated with increased inflammation following SEA 
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inhalation. However, it is not known which receptor SEA binds on AMs to and how the 
macrophages process the enterotoxin intracellularly. Furthermore, usage of alternative AM 
ablation models (e.g. intrathoracic administration of DT in CD169-DTR mice) will establish a 
more direct link between AMs and S. aureus enterotoxins. These future studies may help to 
determine at-risk patients who may be more susceptible to S. aureus enterotoxin exposure.  
Thirdly, chapter 4 uncovered that CD54 is a critical player in SEA-evoked lung injury 
and blocking CD54 many hours after the exposure significantly reduced inflammation and 
tissue damage (275). Although it was shown that therapeutic CD54 blockade significantly 
reduces T cell recruitment to lung, it is also possible that the direct engagement of CD54 
with its binding partners (e.g. CD11a) plays a vital role in triggering damage to endothelial 
cells (196, 280). Furthermore, it will be interesting to explore whether such pathways are 
dependent on the presence of an antigen (i.e. SEA) or whether they can occur 
independently of TCR binding. 
Finally, it will be critical to further establish the causal relationship between 
superantigens and the pathogenesis of SIRS/sepsis and ALI/ARDS in humans. Prior studies 
have preferentially focused on studying Gram-negative bacteria and particularly the effects 
of LPS on eliciting immune response and cell injury. However, a recent study showed that 
47% of patients in intensive care units with a serious infection were infected with Gram-
positive bacteria and S. aureus was present in 20% of cases (87).  Thus, superantigens may 
represent a crucial trigger of SIRS/sepsis and ALI/ARDS.  There is currently no standard 
test used to detect superantigens in patients. Ideally, such test would detect superantigen 
proteins in anterior nares, blood or BAL fluid of patients who are at risk or presenting with 
symptoms of SIRS or ALI. Detection of superantigen proteins would be preferable to 
analyzing gene expression in S. aureus strains that were extracted from patients as 
superantigens are not necessarily transcribed and translated continuously (10). 
Alternatively, a functional immunoassay could be used that would detect clonal T cell 
activation or expansion or the downstream effects, such as IL-2 production in a co-culture 
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assay of naïve T cells with BAL fluid or serum obtained from patients (183, 254). This would 
also demonstrate that the immune system is responding as some individuals may have 
neutralizing antibodies to superantigens.  
 In conclusion, S. aureus enterotoxins and other superantigens are potent but 
currently underrated virulence factors. Unlike LPS and other pathogen associated molecular 
patterns (PAMPs), they trigger a robust immune response through oligoclonal activation of T 
cells rather than pattern recognition receptors (PRRs). T cells then orchestrate other arms of 
the immune system, which results in systemic inflammatory response and organ damage.  
Thus, S. aureus enterotoxins and other superantigens trigger unique pathways that merit 
further investigation, especially in the field of SIRS/sepsis and ALI/ARDS. Understanding 
these mechanisms will enhance our knowledge of these devastating diseases and may lead 
to discovery of novel therapeutic targets.   
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FIGURE 6.1: Summary of systemic inflammatory responses following SEA inhalation. 
SEA  (marked as ) enters the airways through the nasal cavity and reaches the lung ✦
mucosa and individual alveoli. SEA gets trapped inside alveolar macrophages (AMs) which 
likely reduces the amount of the enterotoxin that gets into the circulation and the subsequent 
inflammatory response (Chapter 5; unpublished). SEA can be found in the blood within 
minutes of inhalation and it disseminates systemically. In LNs and spleen, SEA binds 
dendritic cells (DCs), particularly migratory DCs, and activates SEA-specific T cells (e.g. 
Vβ3+) inducing a robust cytokine and chemokine release (marked as ). More specifically, 
TNF and CD28 signaling play unique but complementary roles in triggering systemic 
migration of the innate immune cells (neutrophils and inflammatory monocytes) from the 
bone marrow and likely also the marginated pool. The chemotactic gradient recruits the 
circulating neutrophils and monocytes into spleen and LNs, particularly the T cell zone 
(Chapter 3; (183)). Because SEA-specific T cells are also found in the lung under 
homeostatic conditions, they also become activated and secrete cytokines and chemokines, 
including CXCL1 and IL-12p40 (Chapter 4; (275)). Furthermore, the cytokine IL-2 plays a 
role in triggering IL-17 release from γδ T cells aiding the recruitment of neutrophils ((30); A. 
Ménoret, unpublished work). The pulmonary immune responses and/or the circulating 
cytokines induce activation of pulmonary endothelial cells, including pSTAT1 and MHC II 
upregulation and changes in gene transcription (Chapter 4; (275)).   
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FIGURE 6.2: Summary of pulmonary inflammatory responses following SEA 
inhalation. Two days after SEA inhalation, the population of SEA-specific T cells (e.g. Vβ3+) 
becomes significantly expanded within the lymphoid tissues. SEA-specific T cells and 
particularly CD8+ T cells then accumulate in the lung (process dependent on CD4+ T cell 
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help) and induce production of cytokines and chemokines, including IFNγ, IL-6, CXCL1 and 
CCL2 ((39) and also Chapter 4; (275)). These factors induce the recruitment of NK cells, 
neutrophils and monocytes to the lung ((30) and also Chapter 4; (275)). The population of 
pulmonary endothelial cells downregulates the expression of eNOS and upregulates Fas 
and CD54 (marked as ). These cumulative inflammatory responses are largely dependent |
on CD54 expression and trigger injury to epithelial and endothelial cells (marked as grey 
cells with injury markers shown as ) and increased lung permeability, further propagating ✷
the inflammation within the tissue (Chapter 4; (275)). 
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